US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
WO1989007142A1
(en)
*
|
1988-02-05 |
1989-08-10 |
Morrison Sherie L |
Domain-modified constant region antibodies
|
EP0359096B1
(de)
*
|
1988-09-15 |
1997-11-05 |
The Trustees Of Columbia University In The City Of New York |
Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
|
GB8905669D0
(en)
*
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
GB8916400D0
(en)
*
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
GB9206422D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
CA2093494A1
(en)
*
|
1992-04-17 |
1993-10-18 |
Keisuke Iwata |
Method for the elimination of non-specific reactions in immuno-assays
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
US5885573A
(en)
*
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
CA2186455A1
(en)
*
|
1994-03-29 |
1995-10-05 |
Raymond John Owens |
Antibodies against e-selectin
|
AU3382595A
(en)
*
|
1994-07-29 |
1996-03-04 |
Smithkline Beecham Corporation |
Novel compounds
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6410008B1
(en)
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
US7803904B2
(en)
*
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US6551593B1
(en)
*
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6001973A
(en)
*
|
1996-04-26 |
1999-12-14 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
US6451308B1
(en)
|
1996-04-26 |
2002-09-17 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
ATE248192T1
(de)
|
1996-06-07 |
2003-09-15 |
Neorx Corp |
HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
|
US7247302B1
(en)
*
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
EP1746107B1
(de)
*
|
1998-04-02 |
2014-12-17 |
Genentech, Inc. |
Antikörpervarianten und deren Fragmente
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
EP1068241B1
(de)
*
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antikörper varianten und fragmente davon
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
MXPA00010070A
(es)
*
|
1998-04-15 |
2004-03-10 |
Lexigen Pharm Corp |
Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
|
GB9809951D0
(en)
*
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
ES2331901T3
(es)
|
1998-06-12 |
2010-01-19 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
|
US7553487B2
(en)
*
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
AU2004233493B2
(en)
*
|
1999-01-15 |
2008-10-09 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
SK10042001A3
(sk)
|
1999-01-15 |
2001-12-03 |
Biogen, Inc. |
Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000047625A2
(en)
|
1999-02-12 |
2000-08-17 |
Genetics Institute, Inc. |
Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
EP1161451A4
(de)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
Menschliches alpha-endokin und verfahren zu seiner verwendung
|
AR022952A1
(es)
|
1999-03-19 |
2002-09-04 |
Smithkline Beecham Corp |
ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
|
ES2291205T3
(es)
*
|
1999-05-19 |
2008-03-01 |
Merck Patent Gmbh |
Expresion y exportacion de proteinas interferon alfa como proteinas de fusion fc.
|
SI2314315T1
(sl)
*
|
1999-06-01 |
2015-04-30 |
Biogen Idec Ma Inc. |
Blokirno monoklonsko protitelo proti humani alfa1 i-domeni vla-1 in njegova uporaba za zdravljenje vnetnih obolenj
|
AU779612C
(en)
|
1999-07-02 |
2005-12-15 |
Genentech Inc. |
Peptide compounds that bind HER2
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
RU2263118C2
(ru)
*
|
1999-08-09 |
2005-10-27 |
Лексиген Фармасьютикэлс Корп. |
Комплексы антител с несколькими цитокинами
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
WO2001036489A2
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
EP2289550A3
(de)
*
|
2000-01-27 |
2012-02-15 |
MedImmune, LLC |
Neutralisierende Antikörper mit ultrahoher Affinität
|
AU2001240020B9
(en)
|
2000-03-01 |
2008-12-04 |
Medimmune, Llc |
High potency recombinant antibodies and method for producing them
|
AU4314801A
(en)
*
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
ES2431834T3
(es)
|
2000-03-07 |
2013-11-28 |
The Johns Hopkins University |
Anticuerpos de sialoadhesina factor-2
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU5345901A
(en)
*
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
CA2408691A1
(en)
|
2000-05-12 |
2001-11-22 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
NZ522700A
(en)
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
MXPA02012734A
(es)
*
|
2000-06-29 |
2003-04-25 |
Merck Patent Gmbh |
Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
|
IL154925A0
(en)
|
2000-09-14 |
2003-10-31 |
Beth Israel Hospital |
Modulation of il-2 and il-15-mediated t cell responses
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
US7658921B2
(en)
*
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
EP1355666B1
(de)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Verwendung von "repulsive guidance molecule" (rgm) und von dessen modulatoren
|
EP1683865A3
(de)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Säugerproteine und insbesondere CD200
|
KR20090010127A
(ko)
*
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
MXPA03009390A
(es)
|
2001-04-13 |
2004-01-29 |
Biogen Inc |
Anticuerpos para integrina vla-1.
|
ATE502053T1
(de)
|
2001-05-03 |
2011-04-15 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
WO2002098897A2
(en)
|
2001-06-01 |
2002-12-12 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US7858095B2
(en)
|
2001-07-24 |
2010-12-28 |
Astellas Us Llc |
Method for treating or preventing sclerotic disorders using CD-2 binding agents
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
JP4461210B2
(ja)
*
|
2001-08-27 |
2010-05-12 |
ジェネンテック, インコーポレイテッド |
抗体発現系とその構築法
|
EP1432431B1
(de)
|
2001-10-04 |
2017-05-10 |
Genetics Institute LLC |
Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21
|
US7053202B2
(en)
|
2001-10-19 |
2006-05-30 |
Millennium Pharmaceuticals, Inc. |
Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
|
MXPA04003798A
(es)
*
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
US7186804B2
(en)
|
2001-12-04 |
2007-03-06 |
Emd Lexigen Research Center Corp. |
IL-2 fusion proteins with modulated selectivity
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
CN101683520A
(zh)
|
2002-04-09 |
2010-03-31 |
比奥根艾迪克Ma公司 |
用于治疗tweak相关病症的方法
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
JP4585968B2
(ja)
|
2002-05-10 |
2010-11-24 |
パーデュー・リサーチ・ファウンデーション |
EphA2アゴニストモノクローナル抗体およびその使用法
|
DE60334453D1
(de)
*
|
2002-05-30 |
2010-11-18 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
EP2371389A3
(de)
*
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
CA2499816C
(en)
|
2002-09-27 |
2013-07-30 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US20040115213A1
(en)
*
|
2002-10-04 |
2004-06-17 |
Chapman Stanley Willetts |
Use of IL-2 receptor antibodies
|
JP4988201B2
(ja)
|
2002-10-16 |
2012-08-01 |
ユーロ−セルティーク エス.エイ. |
細胞結合性ca125/o772pに結合する抗体およびその使用方法
|
EA201492217A1
(ru)
|
2002-10-17 |
2015-06-30 |
Генмаб А/С |
Человеческие моноклональные антитела против cd20
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
EP1578447A4
(de)
*
|
2002-10-31 |
2009-06-03 |
Genentech Inc |
Verfahren und zusammensetzungen zur erhöhung der antikörper-produktion
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
PT1572748E
(pt)
*
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
EP2368578A1
(de)
*
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP2052713A3
(de)
|
2003-01-13 |
2009-05-20 |
Macrogenics, Inc. |
Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US20060188512A1
(en)
*
|
2003-02-01 |
2006-08-24 |
Ted Yednock |
Active immunization to generate antibodies to solble a-beta
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
AU2004217442A1
(en)
|
2003-03-04 |
2004-09-16 |
Genzyme Corporation |
Endothelial cell specific antibodies and uses thereof
|
US7495085B2
(en)
|
2003-03-14 |
2009-02-24 |
Wyeth |
Antibodies against human or mouse IL-21 receptor
|
GB0306309D0
(en)
|
2003-03-19 |
2003-04-23 |
Glaxo Group Ltd |
Method of treatment
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
US20040208876A1
(en)
|
2003-04-18 |
2004-10-21 |
Kim Kyung Jin |
Monoclonal antibodies to hepatocyte growth factor
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
PT2298347E
(pt)
|
2003-05-06 |
2016-01-29 |
Biogen Hemophilia Inc |
Proteínas quiméricas de fator de coagulação para o tratamento de um disturbio hemostático
|
RU2369636C2
(ru)
*
|
2003-05-23 |
2009-10-10 |
Уайт |
Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
|
PE20050627A1
(es)
*
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
JP2007505643A
(ja)
*
|
2003-06-12 |
2007-03-15 |
イーライ リリー アンド カンパニー |
融合蛋白質
|
CA2528591C
(en)
*
|
2003-06-12 |
2013-01-08 |
Eli Lilly And Company |
Glp-1 analog fusion proteins
|
US20040254108A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
DK1639014T3
(da)
*
|
2003-06-13 |
2011-01-17 |
Biogen Idec Inc |
Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
|
US20050232931A1
(en)
*
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
EP1641826A2
(de)
|
2003-06-27 |
2006-04-05 |
Biogen Idec MA Inc. |
Verwendung der hydrophoben-interaktions-chromatographie oder hinge-regionen modifikationen zur herstellung homogener antikörperlösung
|
EP2292264A3
(de)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methoden und Zusammensetzungen zur Erhöhung der Wirksamkeit von therapeutischen Antikörper unter Verwendung von Verbindungen, die NK-Zellen potenzieren
|
EP1664115A2
(de)
*
|
2003-08-01 |
2006-06-07 |
Genentech, Inc. |
Antikörper cdr polypeptid-sequenzen mit limitierter diversität
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US20050152894A1
(en)
*
|
2003-09-05 |
2005-07-14 |
Genentech, Inc. |
Antibodies with altered effector functions
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
EP1675609A1
(de)
|
2003-10-20 |
2006-07-05 |
Biogen Idec MA Inc. |
Therapeutische schemata für baff-antagonsiten
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
PL2383295T3
(pl)
|
2003-12-10 |
2015-08-31 |
Squibb & Sons Llc |
IP-10 przeciwciała i ich zastosowanie
|
CN102344491B
(zh)
|
2003-12-10 |
2015-03-11 |
梅达雷克斯有限责任公司 |
干扰素α抗体及其用途
|
MXPA06000176A
(es)
|
2003-12-10 |
2006-06-27 |
Millennium Pharm Inc |
Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
US20050227324A1
(en)
|
2003-12-19 |
2005-10-13 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
US20050249723A1
(en)
*
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
SI1707627T1
(sl)
*
|
2003-12-25 |
2013-02-28 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistiäśen mutant anti-cd40 protitelesa
|
ES2305886T3
(es)
|
2003-12-30 |
2008-11-01 |
Merck Patent Gmbh |
Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
|
PT1699821E
(pt)
*
|
2003-12-31 |
2012-08-23 |
Merck Patent Gmbh |
Proteína de fusão fc-eritropoietina com farmacocinética melhorada
|
PT1704166E
(pt)
|
2004-01-07 |
2015-09-04 |
Novartis Vaccines & Diagnostic |
Anticorpo monoclonal específico de m-csf e respetivos usos
|
CN1918178B
(zh)
*
|
2004-01-12 |
2012-08-22 |
应用分子进化公司 |
Fc区变体
|
AU2005206277B2
(en)
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
US20050169970A1
(en)
*
|
2004-02-02 |
2005-08-04 |
Unilever Bestfoods, North America |
Food composition with fibers
|
AU2005227326B2
(en)
*
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
EP1786463A4
(de)
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antikörper gegen nogo-rezeptor
|
EP1730191B1
(de)
|
2004-03-30 |
2011-07-06 |
Glaxo Group Limited |
Immunglobuline gegen menschlisches osm
|
US7794713B2
(en)
*
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
PL1737891T3
(pl)
*
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
JP5367982B2
(ja)
*
|
2004-04-16 |
2013-12-11 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
EP1750747A1
(de)
|
2004-05-07 |
2007-02-14 |
Astellas US LLC |
Lösliches lfa-3 polypeptid zur behandlung viraler erkrankungen
|
MXPA06012601A
(es)
*
|
2004-05-10 |
2007-05-10 |
Macrogenics Inc |
Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
CA2566333A1
(en)
*
|
2004-05-19 |
2005-12-01 |
Wyeth |
Modulation of immunoglobulin production and atopic disorders
|
WO2005118864A2
(en)
|
2004-05-28 |
2005-12-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
CN102973947A
(zh)
|
2004-06-01 |
2013-03-20 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
US7501121B2
(en)
*
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
US20090098142A1
(en)
*
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
PT1781705E
(pt)
|
2004-06-21 |
2014-12-23 |
Medarex Llc |
Anticorpos contra recetor i do interferão alfa e as suas utilizações
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
DK2471813T3
(en)
*
|
2004-07-15 |
2015-03-02 |
Xencor Inc |
Optimized Fc variants
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
AU2005274905B2
(en)
*
|
2004-08-04 |
2010-12-23 |
Mentrik Biotech, Llc |
Variant Fc regions
|
US7476724B2
(en)
*
|
2004-08-05 |
2009-01-13 |
Genentech, Inc. |
Humanized anti-cmet antibodies
|
KR20070057789A
(ko)
*
|
2004-08-05 |
2007-06-07 |
와이어쓰 |
인터루킨-21 수용체 활성의 상쇄
|
AU2005277641A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
CN101052654A
(zh)
*
|
2004-08-19 |
2007-10-10 |
健泰科生物技术公司 |
具有改变的效应子功能的多肽变体
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
MX2007002856A
(es)
*
|
2004-09-02 |
2007-09-25 |
Genentech Inc |
Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
|
KR101364276B1
(ko)
*
|
2004-09-03 |
2014-02-20 |
제넨테크, 인크. |
인간화 항-베타7 길항제 및 그의 용도
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1797182A2
(de)
|
2004-10-05 |
2007-06-20 |
Wyeth a Corporation of the State of Delaware |
Verfahren und zusammensetzungen zur verbesserung der herstellung rekombinanter proteine
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
WO2006050166A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20060222653A1
(en)
*
|
2004-11-12 |
2006-10-05 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
WO2006055871A2
(en)
|
2004-11-19 |
2006-05-26 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
WO2006071441A2
(en)
|
2004-11-30 |
2006-07-06 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
SG157423A1
(en)
|
2004-12-02 |
2009-12-29 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
EP1833509A4
(de)
*
|
2004-12-03 |
2008-12-03 |
Biogen Idec Inc |
Verzögerung oder verhinderung des einsetzens von multipler sklerose
|
BRPI0519000A2
(pt)
*
|
2004-12-09 |
2008-12-23 |
Merck Patent Gmbh |
variantes de il-7 com imunogenicidade reduzida
|
JP2008524247A
(ja)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのアミロイドβ抗体
|
EP1838854B1
(de)
*
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antikörper, die Amyloid-Peptide erkennen
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
EP1674479A1
(de)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
|
WO2006070286A2
(en)
|
2004-12-28 |
2006-07-06 |
Innate Pharma S.A. |
Monoclonal antibodies against nkg2a
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
EP1858925A2
(de)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antikörper und fc-fusionsproteine mit veränderter immunogenizität
|
US7700099B2
(en)
*
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
MX2007009810A
(es)
*
|
2005-02-14 |
2008-03-07 |
Wyeth Corp |
Uso de interleucina-17f en diagnostico y terapia de inflamacion de vias aereas.
|
MX2007009811A
(es)
*
|
2005-02-14 |
2007-09-07 |
Wyeth Corp |
Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos.
|
WO2006089133A2
(en)
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
EP2332408B1
(de)
|
2005-02-17 |
2013-11-13 |
Biogen Idec MA Inc. |
Behandlung neurologischer Störungen
|
CN101166542A
(zh)
|
2005-03-02 |
2008-04-23 |
比奥根艾迪克Ma公司 |
用于治疗th2介导的疾病的kim-1抗体
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
WO2006105062A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
BRPI0609655A2
(pt)
|
2005-03-31 |
2010-03-16 |
Agensys Inc |
anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
|
KR20140068234A
(ko)
|
2005-03-31 |
2014-06-05 |
더 제너럴 하스피탈 코포레이션 |
Hgf/hgfr 활성의 모니터링 및 조정
|
TW200720289A
(en)
*
|
2005-04-01 |
2007-06-01 |
Hoffmann La Roche |
Antibodies against CCR5 and uses thereof
|
PL3264094T3
(pl)
|
2005-04-04 |
2021-04-19 |
Biogen Ma Inc. |
Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2606102C
(en)
*
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
MY148086A
(en)
*
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
AU2006244180B2
(en)
|
2005-05-06 |
2012-03-01 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
MX2007013924A
(es)
*
|
2005-05-09 |
2008-01-28 |
Glycart Biotechnology Ag |
Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
EP1885388B1
(de)
|
2005-05-10 |
2013-09-11 |
Biogen Idec MA Inc. |
Behandlung und beurteilung von entzündlichen erkrankungen
|
DK2559690T3
(en)
|
2005-05-10 |
2016-04-25 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
|
ME00261B
(me)
|
2005-05-27 |
2011-02-10 |
Biogen Idec Inc |
Tweak vezujuća antitijela
|
US20070020660A1
(en)
*
|
2005-06-06 |
2007-01-25 |
Burczynski Michael E |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
UA96922C2
(en)
*
|
2005-06-30 |
2011-12-26 |
Эббот Леборейториз |
Il-12/p40 binding protein
|
EP1899477A4
(de)
*
|
2005-07-01 |
2010-01-20 |
Medimmune Inc |
Integrierter ansatz zur erzeugung von heilmitteln mit multidomänen-proteinen
|
NZ564592A
(en)
|
2005-07-01 |
2011-11-25 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
EP1904652A2
(de)
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
|
CA2614640A1
(en)
*
|
2005-07-11 |
2007-01-18 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
KR20080030673A
(ko)
*
|
2005-07-21 |
2008-04-04 |
젠맵 에이/에스 |
Fc 수용체와 결합하는 항체 약품 성분에 대한 효력 검정
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
US20080233118A1
(en)
*
|
2005-07-28 |
2008-09-25 |
Novartis Ag |
Uses Of Antibody To M-Csf
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
JP2012228248A
(ja)
*
|
2005-08-19 |
2012-11-22 |
Abbott Lab |
二重可変ドメイン免疫グロブリン及びその使用
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
PT1915397E
(pt)
|
2005-08-19 |
2015-04-30 |
Univ Pennsylvania |
Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
|
SG2014010029A
(en)
*
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
EP2500359A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
CA2620802A1
(en)
|
2005-08-31 |
2007-03-08 |
Schering Corporation |
Engineered anti-il-23 antibodies
|
DE602006009834D1
(de)
|
2005-09-01 |
2009-11-26 |
Schering Corp |
Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
|
EP1762575A1
(de)
*
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
|
US20070065437A1
(en)
|
2005-09-12 |
2007-03-22 |
Greg Elson |
Anti-CD3 antibody formulations
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
WO2007047578A2
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Inc. |
Cell display of antibody libraries
|
WO2007045477A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Human antibodies against il-13 and therapeutic uses
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
EA014900B1
(ru)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
CA2629147A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
|
EP1790664A1
(de)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
|
KR101866623B1
(ko)
*
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 1가 항체 및 그의 제조 방법
|
RU2432362C2
(ru)
*
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
DK1954718T3
(en)
|
2005-11-30 |
2014-12-15 |
Abbvie Inc |
Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
AU2006338198B2
(en)
*
|
2005-12-02 |
2012-04-26 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
NZ568551A
(en)
|
2005-12-08 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to Fucosyl-GM1 and methods using anti-Fucosyl-GM1
|
CN103396485B
(zh)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
靶向多聚泛蛋白的方法和组合物
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
EP1966238B1
(de)
|
2005-12-30 |
2012-04-25 |
Merck Patent GmbH |
Interleukin-12p40-varianten mit verbesserter stabilität
|
ES2365046T3
(es)
|
2005-12-30 |
2011-09-21 |
Merck Patent Gmbh |
Anticuerpos anti-cd19 con inmunogenicidad reducida.
|
CA2638785C
(en)
|
2006-01-05 |
2017-02-21 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
ES2709672T3
(es)
|
2006-01-12 |
2019-04-17 |
Alexion Pharma Inc |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
BRPI0706935A2
(pt)
|
2006-01-20 |
2011-04-19 |
Genentech Inc |
anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2
|
JP2009525986A
(ja)
*
|
2006-02-03 |
2009-07-16 |
メディミューン,エルエルシー |
タンパク質製剤
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
WO2007103469A2
(en)
|
2006-03-06 |
2007-09-13 |
Aeres Biomedical Ltd. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
EP1999470A4
(de)
*
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
Identifizierung und herstellung von antikörpern mit variierenden schweren ketten und anwendungsverfahren dafür
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
BRPI0708998A2
(pt)
*
|
2006-03-21 |
2011-06-21 |
Wyeth Corp |
anticorpo que se liga especificamente ao rage; anticorpo quimérico ou um fragmento de ligação rage do mesmo; anticorpo humanizado ou um fragmento de ligação rage do mesmo; anticorpo humanizado que se liga especificamente ao rage ou um fragmento de ligação rage do mesmo; anticorpo que se liga especificamente ao rage e bloqueia a ligação de um parceiro corporal rage; ácido nucléico isolado; método de tratamento de um indivìduo que tem uma doença ou transtorno relacionado com rage; método de tratamento de sepse ou choque séptico em um indivìduo humano; método de tratamento de listeriose sistêmica em um indivìduo humano; e método de inibir a ligação de um parceiro de ligação rage (rage-bp), o rage em um indivìduo mamìfero
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
AR059922A1
(es)
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
US7695928B2
(en)
|
2006-04-10 |
2010-04-13 |
Genentech, Inc. |
Disheveled PDZ modulators
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
TWI395754B
(zh)
*
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US8592149B2
(en)
|
2006-04-27 |
2013-11-26 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
EP2839843B1
(de)
*
|
2006-05-25 |
2018-06-20 |
Biogen MA Inc. |
VLA-1-Antagonisten zur Verwendung bei der Behandlung von Schlaganfall
|
WO2007139972A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Wyeth |
Expression of the cysteine protease legumain in vascular and inflammatory diseases
|
CA2660592C
(en)
|
2006-05-26 |
2016-07-12 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
WO2007145941A2
(en)
*
|
2006-06-06 |
2007-12-21 |
Tolerrx, Inc. |
Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
|
SG172687A1
(en)
*
|
2006-06-06 |
2011-07-28 |
Genentech Inc |
Compositions and methods for modulating vascular development
|
KR20090027227A
(ko)
*
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-dll4 항체 및 이의 사용 방법
|
SG10201504662WA
(en)
*
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
DK2029173T3
(en)
|
2006-06-26 |
2016-11-07 |
Macrogenics Inc |
FC-RIIB-specific antibodies and methods of use thereof
|
EP2032159B1
(de)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2657681C
(en)
*
|
2006-07-14 |
2019-03-19 |
Ac Immune S.A. |
Humanized antibodies against beta amyloid protein
|
WO2008010101A2
(en)
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
EP2057193B1
(de)
*
|
2006-08-04 |
2013-12-18 |
Novartis AG |
Ephb3-spezifischer antikörper und verwendungen davon
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
TW200817438A
(en)
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
SI2059535T1
(sl)
|
2006-08-18 |
2014-03-31 |
Novartis Ag |
Za prlr specifiäśno protitelo in njegove uporabe
|
WO2008025032A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Zymogenetics, Inc. |
Soluble il-27 receptor
|
AU2007290570C1
(en)
|
2006-08-28 |
2013-08-15 |
Kyowa Kirin Co., Ltd. |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
BRPI0715660B8
(pt)
|
2006-09-01 |
2021-05-25 |
Zymogenetics Inc |
anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
|
AU2007292890A1
(en)
|
2006-09-05 |
2008-03-13 |
Medarex, Inc. |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
ES2817756T3
(es)
|
2006-09-08 |
2021-04-08 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleuquina-13
|
CA2662340C
(en)
|
2006-09-08 |
2016-08-02 |
Medimmune, Llc |
Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
BRPI0717512A2
(pt)
*
|
2006-09-29 |
2013-11-19 |
Hoffmann La Roche |
Anticorpos contra ccr5 e usos dos mesmos
|
DK2486941T3
(en)
|
2006-10-02 |
2017-06-26 |
Squibb & Sons Llc |
HUMAN ANTIBODIES BINDING CXCR4 AND APPLICATIONS THEREOF
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
RU2486201C2
(ru)
*
|
2006-10-12 |
2013-06-27 |
Дженентек, Инк. |
Антитела к лимфотоксину-альфа
|
EP2407548A1
(de)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
|
AU2007319604B2
(en)
|
2006-10-19 |
2011-03-24 |
Csl Limited |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
PL2068922T3
(pl)
|
2006-10-19 |
2012-11-30 |
Csl Ltd |
Przeciwciała anty-IL-13R alfa1 i ich zastosowania
|
JP5732182B2
(ja)
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
LT2845866T
(lt)
|
2006-10-27 |
2017-07-10 |
Genentech, Inc. |
Antikūnai ir imunokonjugatai bei jų panaudojimas
|
BRPI0718118A2
(pt)
|
2006-10-27 |
2017-05-30 |
Lpath Inc |
composições e métodos para ligação de sphingosine-1-fosfato
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
MX2009004718A
(es)
|
2006-11-02 |
2009-06-19 |
Acceleron Pharma Inc |
Antagonistas de receptor de alk1 y ligando y sus usos.
|
EP2097447A4
(de)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
Monoklonale menschliche antikörper gegen btla und verfahren zu ihrer verwendung
|
CN101641106A
(zh)
*
|
2006-11-15 |
2010-02-03 |
功能遗传学股份有限公司 |
抗-tsg101抗体及其用于治疗病毒感染的用途
|
CA2670368C
(en)
*
|
2006-11-21 |
2018-05-29 |
Abbott Laboratories |
Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
|
WO2008067547A2
(en)
|
2006-11-30 |
2008-06-05 |
Research Development Foundation |
Improved immunoglobulin libraries
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
CA2671457C
(en)
|
2006-12-01 |
2017-09-26 |
Medarex, Inc. |
Human antibodies that bind cd22 and uses thereof
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
AR064333A1
(es)
|
2006-12-14 |
2009-04-01 |
Schering Corp |
Anticuerpo anti-tslp de diseno
|
MX2009006277A
(es)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
WO2008079713A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Macrogenics Inc. |
Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
BRPI0806403A2
(pt)
|
2007-02-09 |
2011-09-06 |
Genentech Inc |
anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
|
CN103396489A
(zh)
|
2007-02-23 |
2013-11-20 |
默沙东公司 |
工程改造的抗IL-23p19抗体
|
HUE042172T2
(hu)
|
2007-02-23 |
2019-06-28 |
Merck Sharp & Dohme |
Genetikailag elõállított anti-il-23P19 antitestek
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
US8119133B2
(en)
|
2007-02-28 |
2012-02-21 |
Schering Corporation |
Engineered anti-IL-23R antibodies
|
NZ597915A
(en)
|
2007-02-28 |
2013-08-30 |
Merck Sharp & Dohme |
Combination therapy for treatment of immune disorders
|
EP3199180B1
(de)
|
2007-03-08 |
2022-01-05 |
Humanigen, Inc. |
Ep ha3-antikörper zur behandlung von soliden tumoren
|
EP1970384A1
(de)
|
2007-03-14 |
2008-09-17 |
Ganymed Pharmaceuticals AG |
Monoklonale Antikörper zur Krebsbehandlung
|
TWI417299B
(zh)
|
2007-03-22 |
2013-12-01 |
Biogen Idec Inc |
包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
US20100209434A1
(en)
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
HUE039385T2
(hu)
|
2007-04-12 |
2018-12-28 |
Brigham & Womens Hospital Inc |
ABCB5 rákterápiás célzása
|
CA2684323A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of cerebral amyloid angiopathy
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
FI20075278A0
(fi)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
|
TW200848429A
(en)
*
|
2007-04-23 |
2008-12-16 |
Wyeth Corp |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
AU2008247819B2
(en)
|
2007-05-01 |
2013-02-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
WO2008136694A1
(en)
|
2007-05-04 |
2008-11-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
NO3072525T3
(de)
|
2007-05-14 |
2018-06-30 |
|
|
EP2164514B1
(de)
|
2007-05-21 |
2016-12-14 |
AlderBio Holdings LLC |
Antikörper gegen il-6 und ihre verwendung
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
EP1997832A1
(de)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
AU2008260135A1
(en)
*
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US8604172B2
(en)
*
|
2009-04-17 |
2013-12-10 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
WO2008145142A1
(en)
*
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008145137A2
(en)
*
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
|
EP1997830A1
(de)
*
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
ES2529174T3
(es)
*
|
2007-06-12 |
2015-02-17 |
Ac Immune S.A. |
Anticuerpos humanizados para amiloide beta
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
EP2170390B1
(de)
|
2007-06-14 |
2018-11-07 |
Biogen MA Inc. |
Natalizumab-antikörper-formulierungen
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
CA2958672A1
(en)
*
|
2007-06-15 |
2008-12-18 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
AU2009258063B2
(en)
|
2007-06-21 |
2014-09-25 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
EP3424951A1
(de)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
WO2009006520A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
AR067584A1
(es)
|
2007-07-20 |
2009-10-14 |
Hoffmann La Roche |
Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
|
JP5889529B2
(ja)
|
2007-07-27 |
2016-03-22 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
アミロイド原性疾患の処置
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
CA2696164C
(en)
*
|
2007-08-13 |
2018-06-12 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
JP5607530B2
(ja)
|
2007-09-04 |
2014-10-15 |
コンピュゲン エルティーディー. |
ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
KR101922788B1
(ko)
|
2007-09-26 |
2018-11-27 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
ES2609918T3
(es)
*
|
2007-10-05 |
2017-04-25 |
Genentech, Inc. |
Uso de anticuerpo anti-amiloide beta en enfermedades oculares
|
EP2586795B1
(de)
*
|
2007-10-05 |
2018-05-16 |
Genentech, Inc. |
Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
|
BRPI0818621A8
(pt)
*
|
2007-10-05 |
2018-01-30 |
Ac Immune Sa |
composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
WO2009086320A1
(en)
|
2007-12-26 |
2009-07-09 |
Xencor, Inc |
Fc variants with altered binding to fcrn
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
BRPI0820327A2
(pt)
|
2007-11-02 |
2020-10-06 |
Novartis Ag |
moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
|
PT2514436T
(pt)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 para utilização no tratamento de distúrbios microbianos
|
WO2015164330A1
(en)
|
2014-04-21 |
2015-10-29 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
BRPI0819693A2
(pt)
|
2007-11-30 |
2020-08-18 |
Glaxo Group Limited |
Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
JP5744522B2
(ja)
|
2007-12-07 |
2015-07-08 |
ザイモジェネティクス, インコーポレイテッド |
Il−31に特異的なヒト化抗体分子
|
DK2217268T3
(en)
|
2007-12-07 |
2016-08-15 |
Zymogenetics Inc |
MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
|
EP2222706B2
(de)
|
2007-12-14 |
2016-08-10 |
Novo Nordisk A/S |
Antikörper gegen menschliches nkg2d und gebrauch davon
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
AU2008339576B2
(en)
|
2007-12-21 |
2014-05-22 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
JP5730020B2
(ja)
*
|
2007-12-28 |
2015-06-03 |
ネオトープ バイオサイエンシーズ リミテッド |
アミロイドーシスの処置および予防
|
CA2711771C
(en)
|
2008-01-11 |
2017-01-24 |
Gene Techno Science Co., Ltd. |
Humanized anti-.alpha.9 integrin antibodies and the uses thereof
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
NZ587701A
(en)
*
|
2008-02-04 |
2013-03-28 |
Lay Line Genomics Spa |
Anti-trka antibodies and derivatives thereof
|
RU2528736C2
(ru)
|
2008-02-05 |
2014-09-20 |
Бристоль-Мейерз Сквибб Компани |
Антитела против альфа5-бета 1 и их применение
|
BR122020023189B1
(pt)
*
|
2008-02-08 |
2022-02-01 |
Astrazeneca Ab |
Uso de uma composição farmacêutica compreendendo um anticorpo específico para ifnar1
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009111707A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
NZ601815A
(en)
*
|
2008-03-31 |
2014-10-31 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
CA2720368C
(en)
*
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
NZ588554A
(en)
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
TWI586364B
(zh)
|
2008-05-02 |
2017-06-11 |
艾西利羅製藥公司 |
調節血管新生與周圍細胞組成的方法與組合物
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
EP2291536A4
(de)
|
2008-05-15 |
2013-02-27 |
Selexys Pharmaceuticals Corp |
Antikörper gegen psgl-1 und verfahren zur identifizierung und verwendung
|
BRPI0908665A2
(pt)
*
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
MX2010012616A
(es)
|
2008-05-29 |
2010-12-21 |
Galaxy Biotech Llc |
Anticuerpos monoclonales para factor de crecimiento de fibroblastos basico.
|
CN102112495A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
EP2282770B1
(de)
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
|
US20110177070A1
(en)
*
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
WO2010003108A2
(en)
*
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS
|
NZ590619A
(en)
*
|
2008-07-03 |
2012-08-31 |
Pfenex Inc |
High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
|
US8088803B2
(en)
|
2008-07-08 |
2012-01-03 |
Incyte Corporation |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
EP2810654A1
(de)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin-E2 bindende Proteine und ihre Verwendung
|
RU2011104348A
(ru)
*
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
AR077718A1
(es)
*
|
2008-07-15 |
2011-09-21 |
Genentech Inc |
Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
|
US9182406B2
(en)
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
EP2837388A1
(de)
|
2008-08-05 |
2015-02-18 |
Novartis AG |
Zusammensetzungen und Verfahren für gegen das Komplementprotein C5 gerichtete Antikörper
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010019656A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Wyeth |
Humanized anti-rage antibody
|
EP2166021A1
(de)
*
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoklonale Antikörper zur Krebsbehandlung
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
CN107056951A
(zh)
|
2008-10-02 |
2017-08-18 |
阿帕特夫研究和发展有限公司 |
Cd86拮抗物多靶点结合蛋白
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US8101723B2
(en)
|
2008-11-07 |
2012-01-24 |
Galaxy Biotech, Llc |
Monoclonal antibodies to fibroblast growth factor receptor 2
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
ES2719496T3
(es)
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
GB0821100D0
(en)
*
|
2008-11-18 |
2008-12-24 |
Hansa Medical Ab |
Antibodies
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
AU2009322236B2
(en)
*
|
2008-12-04 |
2013-11-07 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US20110044990A1
(en)
*
|
2008-12-05 |
2011-02-24 |
Sabbadini Roger A |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
CN102300874B
(zh)
|
2008-12-08 |
2015-08-05 |
卡姆普根有限公司 |
Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
US20110250644A1
(en)
|
2008-12-19 |
2011-10-13 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
AR074777A1
(es)
*
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
US8383778B2
(en)
*
|
2009-01-29 |
2013-02-26 |
Abbvie Inc. |
IL-1 binding proteins
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(de)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
|
US9238878B2
(en)
*
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
CA2750477A1
(en)
|
2009-02-19 |
2010-08-26 |
Stephen Duffield |
Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
WO2010094475A1
(en)
|
2009-02-20 |
2010-08-26 |
F. Hoffmann-La Roche Ag |
Method for obtaining immunoglobulin encoding nucleic acid
|
WO2010094499A1
(en)
|
2009-02-20 |
2010-08-26 |
Ganymed Pharmaceuticals Ag |
Methods and compositions for diagnosis and treatment of cancer
|
WO2010095031A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
US20110305693A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Anitigen-binding constructs
|
WO2010097385A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
JP2012518400A
(ja)
|
2009-02-24 |
2012-08-16 |
グラクソ グループ リミテッド |
多価および/または複数特異的rankl結合性構築物
|
EP2400981A4
(de)
*
|
2009-02-26 |
2013-02-27 |
Lpath Inc |
Desgin für humanisierten thrombozytenaktivierungsfaktor-antikörper mittels anti-lipid-antikörper-templates
|
WO2010100056A2
(en)
|
2009-03-02 |
2010-09-10 |
Stichting Top Institute Pharma |
Antibodies against a proliferating inducing ligand (april)
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
RU2011140335A
(ru)
|
2009-03-05 |
2013-04-10 |
Эбботт Лэборетриз |
Связывающие il-17 белки
|
WO2010100200A2
(en)
*
|
2009-03-05 |
2010-09-10 |
Novartis Ag |
Lyophilised antibody formulation
|
EA201101241A1
(ru)
|
2009-03-06 |
2012-04-30 |
Калобайос Фармасьютиклз, Инк. |
Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
EP2233500A1
(de)
*
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimierte Fc Varianten
|
US8597652B2
(en)
|
2009-03-20 |
2013-12-03 |
Genentech, Inc. |
Multispecific anti-HER antibodies
|
HRP20221471T1
(hr)
*
|
2009-03-25 |
2023-02-03 |
Genentech, Inc. |
Protutijela anti-fgfr3 i postupci za njihovu uporabu
|
BRPI1006270B1
(pt)
|
2009-03-25 |
2022-08-16 |
Genentech, Inc |
Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
|
WO2010115786A1
(en)
|
2009-04-01 |
2010-10-14 |
Glaxo Group Limited |
Anti-il-23 immunoglobulins
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
US8093006B2
(en)
|
2009-04-02 |
2012-01-10 |
Hoffmann-La Roche Inc. |
Antibodies against human tweak and uses thereof
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
AU2010233994A1
(en)
|
2009-04-07 |
2011-09-22 |
Roche Glycart Ag |
Bispecific anti-ErbB-3/anti-c-Met antibodies
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
WO2010119991A2
(en)
|
2009-04-17 |
2010-10-21 |
Takeda Pharmaceutical Company Limited |
Novel method of treating cancer
|
SG175166A1
(en)
*
|
2009-04-17 |
2011-11-28 |
Biogen Idec Inc |
Compositions and methods to treat acute myelogenous leukemia
|
JP6141638B2
(ja)
|
2009-04-20 |
2017-06-07 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
カドヘリン−17に特異的な抗体
|
WO2010124113A1
(en)
|
2009-04-23 |
2010-10-28 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
CA2758842A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
Fgfr1c antibody combinations
|
CN102414223A
(zh)
|
2009-04-27 |
2012-04-11 |
诺瓦提斯公司 |
对IL12受体β亚基特异的治疗性抗体的组合物和方法
|
KR101836501B1
(ko)
|
2009-04-27 |
2018-03-08 |
노파르티스 아게 |
근육 성장을 증가시키기 위한 조성물 및 방법
|
WO2010129248A1
(en)
|
2009-05-06 |
2010-11-11 |
Centocor Ortho Biotech Inc. |
Melanocortin receptor binding conjugates
|
AU2010249003B2
(en)
|
2009-05-13 |
2015-08-20 |
Genzyme Corporation |
Anti-human CD52 immunoglobulins
|
CN107252476A
(zh)
|
2009-05-15 |
2017-10-17 |
大学健康网络 |
化合物用于治疗患者体内的cd47+癌细胞或肿瘤的用途
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
CN102448985B
(zh)
|
2009-05-27 |
2015-08-05 |
霍夫曼-拉罗奇有限公司 |
三或四特异性抗体
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
CN102686610A
(zh)
|
2009-06-18 |
2012-09-19 |
辉瑞公司 |
抗刻缺蛋白-1抗体
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
WO2011008517A2
(en)
*
|
2009-06-30 |
2011-01-20 |
Research Development Foundation |
Immunoglobulin fc polypeptides
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
JP2012532619A
(ja)
|
2009-07-16 |
2012-12-20 |
グラクソ グループ リミテッド |
Tnfr1を部分的に阻害するためのアンタゴニスト、用途および方法
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011014438A1
(en)
|
2009-07-31 |
2011-02-03 |
N.V. Organon |
Fully human antibodies to btla
|
WO2011018421A1
(en)
|
2009-08-10 |
2011-02-17 |
Morphosys Ag |
Novel screening strategies for the identification of binders
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
WO2011028228A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
IN2015DN02826A
(de)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
IN2012DN03025A
(de)
|
2009-09-09 |
2015-07-31 |
Ct Se Llc |
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
SG10201408401RA
(en)
|
2009-09-16 |
2015-01-29 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
JP5885664B2
(ja)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
スクリーニング法
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
CN102574921B
(zh)
|
2009-09-29 |
2016-05-04 |
罗切格利卡特公司 |
双特异性死亡受体激动型抗体
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
EP3349010A1
(de)
|
2009-10-11 |
2018-07-18 |
Biogen MA Inc. |
Anti-vla-4-assays
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
CN102666589B
(zh)
|
2009-10-14 |
2014-08-20 |
卡罗拜奥斯制药公司 |
EphA3抗体
|
EP2488658A4
(de)
|
2009-10-15 |
2013-06-19 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
EP2491058A1
(de)
|
2009-10-19 |
2012-08-29 |
F. Hoffmann-La Roche AG |
Modulatoren des hepatozytenwachstumsfaktoraktivators
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック, インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
MX366890B
(es)
|
2009-10-23 |
2019-07-30 |
Millennium Pharm Inc |
Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
NZ599114A
(en)
|
2009-10-27 |
2014-09-26 |
Glaxo Group Ltd |
Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
AU2010313304B2
(en)
|
2009-10-30 |
2015-08-20 |
Janssen Biotech, Inc. |
IL-17A antagonists
|
US8889621B2
(en)
|
2009-10-30 |
2014-11-18 |
New York University |
Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
LT3460056T
(lt)
|
2009-11-02 |
2020-12-28 |
University Of Washington |
Terapinės nukleazės kompozicijos ir būdai
|
BR112012010707B1
(pt)
|
2009-11-04 |
2022-08-30 |
Merck Sharp & Dohme Corp |
Anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, e, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo
|
CA2780143A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
JP5889196B2
(ja)
|
2009-11-11 |
2016-03-22 |
ガニメド ファーマシューティカルズ アーゲー |
クローディン6(cldn6)に特異的な抗体
|
EP2322555A1
(de)
|
2009-11-11 |
2011-05-18 |
Ganymed Pharmaceuticals AG |
Antikörper spezifisch für Claudin 6 (CLDN6)
|
US9775921B2
(en)
*
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
CN102740888B
(zh)
|
2009-11-24 |
2016-10-12 |
奥尔德生物制药公司 |
Il-6抗体及其用途
|
KR101573109B1
(ko)
|
2009-11-24 |
2015-12-01 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
EP2327725A1
(de)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a-bindende Teile mit hoher Blockieraktivität
|
LT2506871T
(lt)
*
|
2009-11-30 |
2016-12-12 |
Janssen Biotech, Inc. |
Antikūno fc mutantai su pašalinta efektoriaus funkcija
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
WO2011067711A2
(en)
|
2009-12-01 |
2011-06-09 |
Compugen Ltd |
Novel heparanase splice variant
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
EP2507267B1
(de)
|
2009-12-02 |
2016-09-14 |
Acceleron Pharma, Inc. |
Zusammensetzungen und verfahren zur erhöhung der serumshaltbarkeit von fc-fusionsproteinen
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
CA2780692C
(en)
|
2009-12-10 |
2018-09-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
EP2513308B1
(de)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation von pilr zur behandlung immunerkrankungen
|
MX2012006626A
(es)
|
2009-12-22 |
2012-06-25 |
Hoffmann La Roche |
Agregacion dependiente de secuencia.
|
CN102822201B
(zh)
|
2009-12-22 |
2014-09-24 |
罗切格利卡特公司 |
抗her3抗体及其用途
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
AU2010343056A1
(en)
*
|
2009-12-29 |
2012-08-02 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
NZ601111A
(en)
|
2010-01-11 |
2014-07-25 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
AR080027A1
(es)
|
2010-01-28 |
2012-03-07 |
Glaxo Group Ltd |
Proteinas de union a cd127
|
CA2789230C
(en)
|
2010-02-08 |
2019-04-02 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
MX2012009167A
(es)
|
2010-02-09 |
2012-08-23 |
Glaxo Group Ltd |
Tratamiento de un trastorno metabolico.
|
CA2789125A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
JP5841072B2
(ja)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
WO2011106723A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Lpath, Inc. |
Anti-paf antibodies
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
SG183847A1
(en)
|
2010-03-04 |
2012-10-30 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
EP2371864A1
(de)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoklonale Antikörper zur Krebsbehandlung
|
EP2550295A1
(de)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Antikörper gegen lrp6
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
NZ602634A
(en)
|
2010-03-26 |
2015-06-26 |
Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
AU2011235569B2
(en)
|
2010-03-29 |
2016-06-30 |
Zymeworks Bc Inc. |
Antibodies with enhanced or suppressed effector function
|
EP2371860A1
(de)
|
2010-04-05 |
2011-10-05 |
Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron |
Den humanen leukaemieinhibierenden Faktor (LIF) erkennender Antikörper und Verwendung von LIF-Antikörpern bei der Behandlung von Krankheiten im Zusammenhang mit ungewollter Zellproliferation
|
CA2795734A1
(en)
|
2010-04-07 |
2011-10-13 |
Abbvie Inc. |
Tnf-.alpha. binding proteins
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
ME03813B
(de)
|
2010-04-16 |
2021-04-20 |
Biogen Ma Inc |
Anti-vla-4 antikörper
|
BR112012027900A2
(pt)
|
2010-04-30 |
2020-05-12 |
Alexion Pharmaceuticals, Inc. |
Anticorpos anti-c5a e métodos para usar os anticorpos
|
EP2566894A1
(de)
|
2010-05-06 |
2013-03-13 |
Novartis AG |
Zusammensetzungen und verfahren zur verwendung von therapeutischen mehrwertigen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
|
US9428583B2
(en)
|
2010-05-06 |
2016-08-30 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
DK2571532T3
(en)
|
2010-05-14 |
2017-08-28 |
Abbvie Inc |
IL-1 BINDING PROTEINS
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
US9169329B2
(en)
|
2010-06-01 |
2015-10-27 |
Ludwig Institute For Cancer Research |
Antibodies directed to the receptor tyrosine kinase c-Met
|
CA2795972A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
MX336001B
(es)
|
2010-06-18 |
2016-01-07 |
Genentech Inc |
Anticuerpos anti-axl y metodos de uso.
|
EP3327035A1
(de)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
JP2013533243A
(ja)
|
2010-06-22 |
2013-08-22 |
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート |
補体成分3のC3d断片に対する抗体
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
EP2588107A1
(de)
|
2010-07-01 |
2013-05-08 |
Takeda Pharmaceutical Company Limited |
Kombination aus einem cmet-hemmer und einem antikörper gegen hgf und/oder cmet
|
EP2404936A1
(de)
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
WO2012006624A2
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Factor ix polypeptides and methods of use thereof
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
EP3508573A1
(de)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systeme für faktor viii-verarbeitung und verfahren davon
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
|
AU2011274528B2
(en)
|
2010-07-09 |
2015-04-23 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
EP2598882B1
(de)
|
2010-07-30 |
2017-07-26 |
AC Immune S.A. |
Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
EP3252072A3
(de)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne und verwendungen davon
|
JP2013541501A
(ja)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
慢性リンパ性白血病(cll)のバイオマーカー
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
NZ703653A
(en)
|
2010-08-13 |
2016-09-30 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a2 항체 및 이의 사용 방법
|
US20130177555A1
(en)
|
2010-08-13 |
2013-07-11 |
Medimmune Limited |
Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
UA114883C2
(uk)
|
2010-08-20 |
2017-08-28 |
Новартіс Аг |
Антитіло до рецептора епідермального фактора росту-3 (her3)
|
KR101586128B1
(ko)
|
2010-08-24 |
2016-01-15 |
에프. 호프만-라 로슈 아게 |
디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체
|
JP5813114B2
(ja)
|
2010-08-25 |
2015-11-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Il−18r1に対する抗体およびその使用
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012027723A1
(en)
|
2010-08-27 |
2012-03-01 |
Stem Centrx, Inc |
Notum protein modulators and methods of use
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
EP2616100B1
(de)
|
2010-09-17 |
2016-08-31 |
Compugen Ltd. |
Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
|
WO2012040617A2
(en)
|
2010-09-23 |
2012-03-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer peptidomimetics
|
JP6126991B2
(ja)
|
2010-09-27 |
2017-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトii型コラーゲンに結合する抗体
|
MX347954B
(es)
|
2010-09-29 |
2017-05-19 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
WO2012045671A1
(en)
|
2010-10-05 |
2012-04-12 |
F. Hoffmann-La Roche Ag |
Antibodies against human tweak and uses thereof
|
NZ609567A
(en)
|
2010-11-05 |
2015-05-29 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
PE20140238A1
(es)
|
2010-11-10 |
2014-03-07 |
Genentech Inc |
Metodos y composiciones para inmunoterapia para enfermedad neural
|
EA029419B1
(ru)
|
2010-11-19 |
2018-03-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Нейтрализующие антитела против ccl20
|
CA2818813C
(en)
|
2010-11-23 |
2020-10-06 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of oral mucositis
|
LT2643352T
(lt)
|
2010-11-23 |
2018-08-10 |
Glaxo Group Limited |
Antigeną onkostatiną m (osm) surišantys baltymai
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
US20130236467A1
(en)
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
CA2819530C
(en)
|
2010-11-30 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
ES2620264T3
(es)
|
2010-12-06 |
2017-06-28 |
Seattle Genetics, Inc. |
Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
|
NZ611428A
(en)
|
2010-12-08 |
2015-07-31 |
Stemcentrx Inc |
Novel modulators and methods of use
|
MX346995B
(es)
|
2010-12-15 |
2017-04-06 |
Wyeth Llc |
Anticuerpos anti-notch1.
|
MY188365A
(en)
|
2010-12-16 |
2021-12-06 |
Genentech Inc |
Diagnosis and treatments relating to th2 inhibition
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
RU2603097C2
(ru)
|
2010-12-21 |
2016-11-20 |
Селексис Фармасьютикалс Корпорейшн |
Антитела к р-селектину и способы их применения и идентификации
|
EP2655417A2
(de)
|
2010-12-21 |
2013-10-30 |
AbbVie Inc. |
Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
KR20130118925A
(ko)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
항-pcsk9 항체 및 사용 방법
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
BR112013017980A2
(pt)
|
2011-01-14 |
2017-06-27 |
Redwood Bioscience Inc |
polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
|
EP3763740A1
(de)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
JP6150734B2
(ja)
|
2011-02-03 |
2017-06-21 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
同種移植片の生存を長期化するための抗cd200抗体の使用
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
TWI666027B
(zh)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
突變介白素-2多肽
|
EP2673302A1
(de)
|
2011-02-11 |
2013-12-18 |
Irm Llc |
Pcsk9-antagonisten
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
KR102003075B1
(ko)
|
2011-02-23 |
2019-07-23 |
에프. 호프만-라 로슈 아게 |
인간 il33r에 대한 항체 및 이의 용도
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
CA2825081A1
(en)
|
2011-02-28 |
2012-09-07 |
Birgit Bossenmaier |
Antigen binding proteins
|
AU2012230899A1
(en)
|
2011-03-21 |
2013-10-10 |
Biodesy, Llc |
Classification of kinase inhibitors using nonlinear optical techniques
|
EP2691417B1
(de)
|
2011-03-29 |
2018-08-01 |
Roche Glycart AG |
Antikörper-fc-varianten
|
KR20190116563A
(ko)
|
2011-03-31 |
2019-10-14 |
머크 샤프 앤드 돔 코포레이션 |
인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
PT2697257T
(pt)
|
2011-04-13 |
2016-12-28 |
Bristol Myers Squibb Co |
Proteínas de fusão fc compreendendo novos ligantes ou arranjos
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
CN105884900A
(zh)
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
US9932386B2
(en)
|
2011-04-20 |
2018-04-03 |
Acceleron Pharma, Inc. |
Endoglin polypeptides and uses thereof
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EP2699256B1
(de)
|
2011-04-21 |
2017-09-27 |
The Regents of the University of Colorado, a body corporate |
Zusammensetzungen und verfahren zur behandlung von neuromyelitis optica
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
KR102006393B1
(ko)
|
2011-04-29 |
2019-08-02 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료적 뉴클레아제 조성물 및 방법
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
PE20141672A1
(es)
|
2011-05-02 |
2014-11-26 |
Millennium Pharm Inc |
FORMULACION PARA ANTICUERPO ANTI-alfa4�7
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
DK2707390T3
(en)
|
2011-05-13 |
2016-02-29 |
Ganymed Pharmaceuticals Ag |
ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6
|
US9346883B2
(en)
|
2011-05-13 |
2016-05-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antibodies against HER3
|
LT2710035T
(lt)
|
2011-05-16 |
2017-06-26 |
F. Hoffmann-La Roche Ag |
Fgfr1 agonistai ir jų naudojimo būdai
|
WO2012162257A2
(en)
|
2011-05-20 |
2012-11-29 |
Alderbio Holdings Llc |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
TWI646111B
(zh)
|
2011-05-20 |
2019-01-01 |
艾爾德生物控股有限責任公司 |
抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途
|
KR102128628B1
(ko)
|
2011-05-20 |
2020-06-30 |
앨더바이오 홀딩스 엘엘씨 |
설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
EA036545B1
(ru)
|
2011-05-25 |
2020-11-20 |
Иннейт Фарма, С.А. |
Анти-kir антитела для лечения воспалительных заболеваний
|
CN106279418A
(zh)
|
2011-05-27 |
2017-01-04 |
葛兰素集团有限公司 |
Bcma(cd269/tnfrsf17)结合蛋白
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2721067B1
(de)
|
2011-06-15 |
2019-07-31 |
F.Hoffmann-La Roche Ag |
Anti-human-epo-rezeptor-antikörper und verfahren zu deren verwendung
|
AU2012269929A1
(en)
|
2011-06-16 |
2013-12-12 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
EA201400046A1
(ru)
|
2011-06-22 |
2014-07-30 |
Ф. Хоффманн-Ля Рош Аг |
Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
|
BR112013032899A2
(pt)
|
2011-06-22 |
2017-01-24 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
anticorpos anti-axl e utilizações dos mesmos
|
JP6033293B2
(ja)
|
2011-06-22 |
2016-11-30 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) |
抗Axl抗体及びその使用
|
EA031181B1
(ru)
|
2011-06-28 |
2018-11-30 |
Оксфорд Байотерепьютикс Лтд. |
Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
WO2013001517A1
(en)
|
2011-06-30 |
2013-01-03 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
CA3158257A1
(en)
|
2011-07-11 |
2013-01-17 |
Ichnos Sciences SA |
Antibodies that bind to ox40 and their uses
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
EP2731970B1
(de)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antikörper mit kreuzreaktion auf makrophagenmigrations-inhibitorfaktor (mif) und d-dopachrom-tautomerase (d-dt)
|
EP2756094B1
(de)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antikörper und ihre verwendungen
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
KR20140054268A
(ko)
|
2011-08-26 |
2014-05-08 |
메리맥 파마슈티컬즈, 인크. |
탠덤 fc 이중특이적 항체
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
AR087918A1
(es)
|
2011-09-19 |
2014-04-23 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
|
CN103814047A
(zh)
|
2011-09-21 |
2014-05-21 |
弗·哈夫曼-拉罗切有限公司 |
通过与TaqMan探针组合的多重PCR从单一抗体产生细胞中获得Fab片段的方法
|
SG2014008809A
(en)
|
2011-09-21 |
2014-04-28 |
Hoffmann La Roche |
Co2 profile cultivation
|
SG11201400881SA
(en)
|
2011-09-23 |
2014-04-28 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
Modified albumin-binding domains and uses thereof to improve pharmacokinetics
|
CN104302668A
(zh)
|
2011-09-23 |
2015-01-21 |
罗氏格黎卡特股份公司 |
双特异性的抗-egfr/抗igf-1r抗体
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
EP3628329B1
(de)
|
2011-09-30 |
2022-08-10 |
Dana-Farber Cancer Institute, Inc. |
Therapeutische peptide mit antikörpern, die an mhc-klasse-1-polypeptid-verwandte sequenz a (mica) binden
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
RS60828B1
(sr)
|
2011-10-11 |
2020-10-30 |
Viela Bio Inc |
Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu
|
JP6190813B2
(ja)
|
2011-10-14 |
2017-08-30 |
ジェネンテック, インコーポレイテッド |
チモーゲン活性化因子
|
US9296826B2
(en)
|
2011-10-14 |
2016-03-29 |
Novartis Ag |
Antibodies and methods for WNT pathway-related diseases
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
BR112014009178A2
(pt)
*
|
2011-10-19 |
2018-09-04 |
Roche Glycart Ag |
métodos, uso, receptor e invenção
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
DK2768851T3
(en)
|
2011-10-21 |
2017-09-18 |
Augurex Life Sciences Corp |
ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
|
BR112014009799A2
(pt)
|
2011-10-24 |
2017-06-13 |
Abbvie Inc |
imunoligantes dirigidos conra tnf
|
EP2771361A1
(de)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Bispezifische gegen tnf und il17 gerichtete immunbinder
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
US8609820B2
(en)
|
2011-10-28 |
2013-12-17 |
Neotope Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
IN2014CN03062A
(de)
|
2011-10-28 |
2015-07-31 |
Hoffmann La Roche |
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773373B1
(de)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Verfahren zur blockierung eines krebsstammzellenwachstums
|
CA2854457A1
(en)
|
2011-11-04 |
2013-05-10 |
David Jenkins |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
CN103906533A
(zh)
|
2011-11-07 |
2014-07-02 |
米迪缪尼有限公司 |
多特异性和多价结合蛋白及其用途
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
EP2785740A1
(de)
|
2011-12-02 |
2014-10-08 |
Eli Lilly and Company |
Anti-glucagon antikörper und verwendungen davon
|
EA036739B1
(ru)
|
2011-12-05 |
2020-12-15 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3)
|
US9416179B2
(en)
|
2011-12-05 |
2016-08-16 |
X-Body, Inc. |
PDGF receptor beta binding polypeptides
|
CN104105709A
(zh)
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
抗her3的结构域ii的表皮生长因子受体3(her3)抗体
|
EP2788024A1
(de)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antikörper-formulierung
|
WO2013083809A1
(en)
|
2011-12-09 |
2013-06-13 |
Amgen Research (Munich) Gmbh |
Prevention of adverse effects caused by epcamxcd3 bispecific antibodies
|
CN104159921B
(zh)
|
2011-12-15 |
2018-05-04 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
WO2013101509A2
(en)
|
2011-12-15 |
2013-07-04 |
Alternative Innovative Technologies Llc |
Hsp70 fusion protein conjugates and uses thereof
|
AU2012355415B2
(en)
|
2011-12-20 |
2017-07-06 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
AP2014007761A0
(en)
|
2011-12-21 |
2014-07-31 |
Novartis Ag |
Compositions and methods for antibodies targeting factor P
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
SG11201403223PA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
US10711056B2
(en)
|
2011-12-28 |
2020-07-14 |
Novelmed Therapeutics, Inc. |
Aglycosylated anti-properdin antibodies
|
WO2013101972A2
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
CA2863328A1
(en)
|
2012-01-12 |
2013-07-18 |
Biogen Idec Ma Inc. |
Chimeric factor viii polypeptides and uses thereof
|
EP2804630B1
(de)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von fgf19-modulatoren
|
PE20141561A1
(es)
|
2012-01-18 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-lrp5 y metodos de uso
|
IN2014DN07149A
(de)
|
2012-01-27 |
2015-04-24 |
Neotope Biosciences Ltd |
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
AU2013216320A1
(en)
|
2012-02-01 |
2014-04-03 |
Compugen Ltd. |
C10RF32 antibodies, and uses thereof for treatment of cancer
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
EP2812350B1
(de)
|
2012-02-11 |
2019-04-03 |
F.Hoffmann-La Roche Ag |
R-spondin-translokationen und verfahren damit
|
TR201808458T4
(tr)
|
2012-02-15 |
2018-07-23 |
Hoffmann La Roche |
FC-reseptör bazlı afinite kromatografisi.
|
EP2822577B1
(de)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Rekombinante faktor-viii-proteine
|
SI3564260T1
(sl)
|
2012-02-15 |
2023-02-28 |
Bioverativ Therapeutics Inc. |
Sestavki faktorja VIII in postopki njegove izdelave in uporabe
|
WO2013123114A2
(en)
|
2012-02-16 |
2013-08-22 |
Santarus, Inc. |
Antibody formulations
|
CN104334580B
(zh)
|
2012-02-24 |
2018-03-30 |
艾伯维施特姆森特克斯有限责任公司 |
抗sez6抗体及使用方法
|
NZ628804A
(en)
|
2012-02-24 |
2017-08-25 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
PT2822575T
(pt)
|
2012-03-03 |
2020-07-02 |
Immungene Inc |
Moléculas de fusão anticorpos-mutante de interferão modificadas
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
WO2013138338A2
(en)
|
2012-03-12 |
2013-09-19 |
Massachusetts Institute Of Technology |
Methods for treating tissue damage associated with ischemia with apoliporotein d
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
EP2825549B1
(de)
|
2012-03-16 |
2018-10-10 |
F. Hoffmann-La Roche SA |
Gleichmässig stabilisierte manipulierte proteine
|
HUE044838T2
(hu)
|
2012-03-20 |
2019-11-28 |
Biogen Ma Inc |
JCV neutralizáló antitestek
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
PL2831113T3
(pl)
|
2012-03-28 |
2018-08-31 |
Sanofi |
Przeciwciała przeciwko ligandom receptora bradykininy B1
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
AU2013244999A1
(en)
|
2012-04-05 |
2014-09-25 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human TWEAK and human IL17 and uses thereof
|
WO2013151762A1
(en)
|
2012-04-05 |
2013-10-10 |
Ac Immune S.A. |
Humanized tau antibody
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
CN106290917B
(zh)
|
2012-04-25 |
2020-06-05 |
比奥德赛公司 |
用于检测蛋白质的变构调节剂的方法
|
EP2841452B1
(de)
|
2012-04-25 |
2023-04-12 |
Momenta Pharmaceuticals, Inc. |
Modifizierte glykoproteine
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
JP6391564B2
(ja)
|
2012-04-30 |
2018-09-19 |
メディミューン,エルエルシー |
低減されたエフェクター機能及び延長された半減期を有する分子、組成物、並びにそれらの使用
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
WO2013169657A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
ES2843054T3
(es)
|
2012-05-10 |
2021-07-15 |
Zymeworks Inc |
Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
DK2852610T3
(en)
|
2012-05-23 |
2018-09-03 |
Glykos Finland Oy |
PRODUCTION OF FUCOSYLED GLYCOPROTEIN
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
RU2014149681A
(ru)
|
2012-05-24 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитела с множественной специфичностью
|
US20150104468A1
(en)
|
2012-06-04 |
2015-04-16 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
EP2859019B1
(de)
|
2012-06-08 |
2018-02-21 |
Glenmark Pharmaceuticals S.A. |
Humanisierten anti-trka antikörper mit aminosäure-substitutionen
|
EP2863940A4
(de)
|
2012-06-08 |
2016-08-10 |
Biogen Ma Inc |
Chimäre gerinnungsfaktoren
|
EP4079316A1
(de)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Prokoagulatorische verbindungen
|
KR101704893B1
(ko)
|
2012-06-15 |
2017-02-08 |
화이자 인코포레이티드 |
Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
|
EP2861624A1
(de)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9-antikörper, formulierungen, dosierung und verfahren zur verwendung
|
WO2013192131A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
EP3138580B1
(de)
|
2012-07-04 |
2021-03-03 |
F. Hoffmann-La Roche AG |
Kovalent verknüpfte antigen-antikörper-konjugate
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
PL2869837T3
(pl)
|
2012-07-04 |
2017-03-31 |
F.Hoffmann-La Roche Ag |
Przeciwciała przeciw teofilinie i sposoby ich stosowania
|
JP6309518B2
(ja)
|
2012-07-05 |
2018-04-11 |
ジェネンテック, インコーポレイテッド |
発現及び分泌システム
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
MX2015000314A
(es)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados.
|
EP2869849A1
(de)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunkonjugate mit anti-cd22-antikörpern
|
KR20150030753A
(ko)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
항-cd79b 항체를 포함하는 면역접합체
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
SG10201913893XA
(en)
|
2012-07-11 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
SI3495387T1
(sl)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
CN110256559B
(zh)
|
2012-07-25 |
2023-05-26 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
BR112015002263A2
(pt)
|
2012-08-02 |
2017-12-12 |
Hoffmann La Roche |
polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AR092219A1
(es)
|
2012-08-23 |
2015-04-08 |
Seattle Genetics Inc |
Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
|
US9381244B2
(en)
|
2012-09-07 |
2016-07-05 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
CN104797601B
(zh)
|
2012-09-12 |
2019-08-30 |
建新公司 |
具有改变的糖基化和降低的效应物功能的包含fc的多肽
|
SG11201500881XA
(en)
|
2012-09-14 |
2015-03-30 |
Hoffmann La Roche |
Method for the production and selection of molecules comprising at least two different entities and uses thereof
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
EP2906598A1
(de)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54-antikörper und verfahren zur verwendung davon
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
TW202014439A
(zh)
|
2012-11-01 |
2020-04-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
BR112015010722A2
(pt)
|
2012-11-09 |
2017-08-22 |
Pfizer |
Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
|
EA201590731A1
(ru)
|
2012-11-13 |
2015-11-30 |
Дженентек, Инк. |
Антитела к гемагглютинину и способы применения
|
EP2733153A1
(de)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
BR112015012014A2
(pt)
|
2012-12-04 |
2017-07-11 |
Abbvie Inc |
proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
|
CA2893767C
(en)
|
2012-12-05 |
2022-11-08 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
AU2013359419B2
(en)
|
2012-12-10 |
2018-03-15 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
ES2756330T3
(es)
|
2012-12-18 |
2020-04-27 |
Novartis Ag |
Polipéptidos de factor de crecimiento insulínico estabilizados
|
CN104884467A
(zh)
|
2012-12-18 |
2015-09-02 |
诺华股份有限公司 |
在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
|
BR112015013861A2
(pt)
|
2012-12-18 |
2017-07-11 |
Novartis Ag |
composições e métodos para proteínas de ação prolongada
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
JP6475167B2
(ja)
|
2012-12-21 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質
|
WO2014106001A2
(en)
|
2012-12-28 |
2014-07-03 |
Abbvie, Inc. |
Dual specific binding proteins having a receptor sequence
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
CN104903352A
(zh)
|
2012-12-28 |
2015-09-09 |
艾伯维公司 |
多价结合蛋白组合物
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
AU2013370171B2
(en)
|
2012-12-28 |
2018-09-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
PE20151289A1
(es)
|
2013-01-02 |
2015-10-05 |
Glenmark Pharmaceuticals Sa |
Anticuerpos que se unen al tl1a y sus usos
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116596A1
(en)
|
2013-01-22 |
2014-07-31 |
Abbvie, Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
WO2014124006A1
(en)
|
2013-02-05 |
2014-08-14 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
EP2762497A1
(de)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispezifische Antikörper gegen CD3-epsilon und BCMA
|
CN111848796A
(zh)
|
2013-02-05 |
2020-10-30 |
英格玛布有限责任公司 |
用于选择针对bcma的抗体的方法
|
EP2762496A1
(de)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Verfahren zur Auswahl von Antikörpern gegen BCMA
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
LT2953969T
(lt)
|
2013-02-08 |
2019-12-10 |
Novartis Ag |
Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
|
MX2015010146A
(es)
|
2013-02-08 |
2016-05-31 |
Novartis Ag |
Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
EP3617220B1
(de)
|
2013-02-12 |
2021-03-24 |
Bristol-Myers Squibb Company |
Rückfaltungsverfahren für protein mit hohem ph-wert
|
ES2813501T3
(es)
|
2013-02-12 |
2021-03-24 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas basados en filtración de flujo tangencial
|
WO2014127215A1
(en)
|
2013-02-15 |
2014-08-21 |
Biogen Idec Ma Inc. |
Optimized factor viii gene
|
WO2014130659A1
(en)
|
2013-02-22 |
2014-08-28 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
CA2896259A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
CA2902263A1
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP2016510755A
(ja)
|
2013-03-06 |
2016-04-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗C−METタンデムFc二重特異性抗体
|
KR20220103204A
(ko)
|
2013-03-11 |
2022-07-21 |
젠자임 코포레이션 |
과글리코실화된 결합 폴리펩티드
|
MX2015012225A
(es)
|
2013-03-13 |
2016-01-08 |
Prothena Biosciences Ltd |
Inmunoterapia tau.
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
CA2906688A1
(en)
|
2013-03-14 |
2014-09-25 |
Parkash S. Gill |
Cancer treatment using antibodies that bind cell surface grp78
|
WO2014143343A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
AU2014244286B2
(en)
|
2013-03-14 |
2018-11-08 |
Duke University |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
ES2812208T3
(es)
|
2013-03-14 |
2021-03-16 |
Bristol Myers Squibb Co |
Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
LT2970449T
(lt)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Viengrandės surišančios molekulės, apimančios n galo abp
|
MX2015012326A
(es)
|
2013-03-15 |
2016-03-08 |
Genentech Inc |
Anticuerpos anti-crth2 y su uso.
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
KR20150128707A
(ko)
|
2013-03-15 |
2015-11-18 |
제넨테크, 인크. |
간암의 진단 및 치료를 위한 조성물 및 방법
|
EP2970908B1
(de)
|
2013-03-15 |
2019-12-25 |
Dana-Farber Cancer Institute, Inc. |
Therapeutische peptide
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
EP2968537A1
(de)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
BR112015023557A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligações dual específicas direcionadas contra tnfa
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
SG11201507333XA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
SI2970422T1
(en)
|
2013-03-15 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
|
CA2907046C
(en)
|
2013-03-15 |
2021-04-20 |
Atyr Pharma, Inc. |
Histidyl-trna synthetase-fc conjugates
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
JP6671276B2
(ja)
|
2013-03-27 |
2020-03-25 |
セダーズ−シナイ メディカル センター |
Tl1a機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
EP2789630A1
(de)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispezifische Antikörper gegen CD3e und ROR1
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
TWI747803B
(zh)
|
2013-04-29 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
人類結合fcrn之經修飾抗體及使用方法
|
MX2015015060A
(es)
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
|
EP3327034A1
(de)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-bindungsverhindernde anti-igf-1r-antikörper und ihre verwendung bei der behandlung von vaskulären augenerkrankungen
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
DK3004174T3
(da)
|
2013-05-31 |
2019-07-22 |
Zymeworks Inc |
Heteromultimerer med reduceret eller nedreguleret effektorfunktion
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
WO2015004632A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize iapp
|
WO2015004633A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize islet-amyloid polypeptide (iapp)
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
WO2015010108A1
(en)
|
2013-07-19 |
2015-01-22 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス,インコーポレイテッド |
Cd37タンパク質に結合する抗体薬物結合体(adc)
|
WO2015016718A1
(en)
|
2013-08-02 |
2015-02-05 |
Bionovion Holding B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
CN105705520B
(zh)
|
2013-08-13 |
2020-09-25 |
赛诺菲 |
纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
WO2015023891A2
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Factor viii-xten fusions and uses thereof
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
DK3036320T3
(da)
|
2013-08-19 |
2021-07-12 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
US20150056199A1
(en)
|
2013-08-22 |
2015-02-26 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
RU2699289C2
(ru)
|
2013-08-26 |
2019-09-04 |
Байонтек Рисерч Энд Дивелопмент, Инк. |
НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
SG11201601416VA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Novel sez6 modulators and methods of use
|
RU2714919C2
(ru)
|
2013-08-30 |
2020-02-21 |
Такеда Гмбх |
Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
|
AU2014317009A1
(en)
|
2013-09-05 |
2016-03-10 |
Aduro Biotech Holdings, Europe B.V. |
CD70-binding peptides and method, process and use relating thereto
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
KR102100419B1
(ko)
|
2013-09-13 |
2020-04-14 |
베이진 스위찰랜드 게엠베하 |
항-pd1 항체 및 이의 치료 및 진단 용도
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
HUE050933T2
(hu)
|
2013-10-02 |
2021-01-28 |
Medimmune Llc |
Semlegesítõ anti-influenza ellenanyagok és alkalmazásaik
|
US20150125397A1
(en)
|
2013-10-06 |
2015-05-07 |
Abbvie Inc. |
Dual specific binding proteins directed against immune cell receptors and autoantigens
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック, インコーポレイテッド |
Nsp4阻害剤及び使用方法
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
MX2016005159A
(es)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
|
EP3851118A1
(de)
|
2013-10-25 |
2021-07-21 |
Acceleron Pharma Inc. |
Endoglinpeptide zur behandlung fibrotischer erkrankungen
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
AR098221A1
(es)
|
2013-11-04 |
2016-05-18 |
Pfizer |
Conjugados de anticuerpo anti-efna4-fármaco
|
EP3069137A1
(de)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organische verbindungen
|
KR20160101909A
(ko)
|
2013-11-07 |
2016-08-26 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
뉴레귤린 알로스테릭 항-her3 항체
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
NZ719092A
(en)
|
2013-11-13 |
2022-05-27 |
Pfizer |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015075635A2
(en)
|
2013-11-19 |
2015-05-28 |
Prothena Biosciences Limited |
Monitoring immunotherapy of lewy body disease from constipation symptoms
|
RU2697098C1
(ru)
|
2013-11-21 |
2019-08-12 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к альфа-синуклеину и способы применения
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
JP2017502002A
(ja)
|
2013-12-09 |
2017-01-19 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌剤の食細胞送達用組成物及び方法
|
SG10201808835QA
(en)
|
2013-12-09 |
2018-11-29 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
EP3527587A1
(de)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-l1-bindungsantagonisten
|
RU2719487C2
(ru)
|
2013-12-17 |
2020-04-17 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с компонентами сигнального пути pd-1, и таксанов
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
LT3083680T
(lt)
|
2013-12-20 |
2020-04-10 |
F. Hoffmann-La Roche Ag |
Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
|
CN106029087A
(zh)
|
2013-12-20 |
2016-10-12 |
印第安纳大学研究及科技有限公司 |
脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
JP6554473B2
(ja)
|
2013-12-24 |
2019-07-31 |
アルゲン−エックス ビーブイビーエー |
FcRnアンタゴニスト及び使用方法
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
CN105873616B
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
共价连接的多肽毒素-抗体缀合物
|
MX2016008190A
(es)
|
2014-01-06 |
2016-10-21 |
Hoffmann La Roche |
Modulos de lanzadera de barrera cerebral sanguinea monovalente.
|
SG10201913697UA
(en)
|
2014-01-10 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
UA119863C2
(uk)
|
2014-01-24 |
2019-08-27 |
Нгм Біофармасьютікалс, Інк. |
Антитіло або його фрагмент, що зв'язується з бета-клото
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
EP3102230B1
(de)
|
2014-02-08 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von morbus alzheimer
|
KR102356951B1
(ko)
|
2014-02-11 |
2022-01-27 |
비스테라, 인크. |
뎅기열 바이러스에 대한 항체 분자 및 그의 용도
|
ES2685424T3
(es)
|
2014-02-12 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-Jagged1 y procedimientos de uso
|
AU2015217278B2
(en)
|
2014-02-14 |
2020-03-19 |
Macrogenics, Inc. |
Improved methods for the treatment of vascularizing cancers
|
EP3104882B1
(de)
|
2014-02-14 |
2019-06-05 |
Centrose, Llc |
Extrazelluläre gezielte wirkstoffkonjugate
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
EP3110446B1
(de)
|
2014-02-28 |
2021-12-01 |
Allakos Inc. |
Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134671A1
(en)
|
2014-03-04 |
2015-09-11 |
Targeson, Inc. |
Molecular imaging contrast agents and uses thereof
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CA2938946A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
MX2016011627A
(es)
|
2014-03-12 |
2016-11-29 |
Novartis Ag |
Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
|
KR20160131082A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg1-3에 특이적인 항-라미닌4 항체
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
CA2938933A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg4-5
|
US20170002077A1
(en)
|
2014-03-13 |
2017-01-05 |
Prothena Biosciences Limited |
Combination treatment for multiple sclerosis
|
US10279021B2
(en)
|
2014-03-14 |
2019-05-07 |
Dana-Faber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring NKG2D pathway function against cancers
|
TWI697500B
(zh)
|
2014-03-14 |
2020-07-01 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
CN106103730B
(zh)
|
2014-03-14 |
2021-06-08 |
豪夫迈·罗氏有限公司 |
用于分泌异源多肽的方法和组合物
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US10995148B2
(en)
|
2014-03-19 |
2021-05-04 |
Genzyme Corporation |
Site-specific glycoengineering of targeting moieties
|
CN113150163A
(zh)
|
2014-03-21 |
2021-07-23 |
X博迪公司 |
双特异性抗原结合多肽
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
CN110841074B
(zh)
|
2014-03-21 |
2023-07-18 |
艾伯维公司 |
抗-egfr抗体及抗体药物偶联物
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
CN106456714A
(zh)
*
|
2014-03-28 |
2017-02-22 |
纽约大学 |
Fgf23融合蛋白
|
UA121112C2
(uk)
|
2014-03-31 |
2020-04-10 |
Дженентек, Інк. |
Антитіло до ox40 та його застосування
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
PL3130606T3
(pl)
|
2014-04-07 |
2022-02-07 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała dwuswoiste aktywujące układ odpornościowy
|
WO2015155694A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
ES2879804T3
(es)
|
2014-04-21 |
2021-11-23 |
D&D Pharmatech Inc |
Agonistas del receptor de TRAIL para el tratamiento de enfermedades fibróticas
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
US20170073401A1
(en)
|
2014-05-02 |
2017-03-16 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for anti-lyst immunomodulation
|
EP4001310A3
(de)
|
2014-05-02 |
2022-08-10 |
MedImmune Limited |
Ionenkanalmodulatoren und verwendungen davon
|
RU2713327C2
(ru)
|
2014-05-05 |
2020-02-04 |
Регенерон Фармасьютикалз, Инк. |
Гуманизированные животные по с5 и с3
|
EP3139960B1
(de)
|
2014-05-07 |
2024-01-17 |
Takeda Pharmaceutical Company Limited |
Flüssigformulierung, enthaltend eine gm-csf-neutralisierende verbindung
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
WO2015174439A1
(ja)
|
2014-05-13 |
2015-11-19 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子
|
CA3175002A1
(en)
|
2014-05-16 |
2015-11-19 |
Ablynx Nv |
Improved immunoglobulin variable domains
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
KR20170003582A
(ko)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
항-gpc3 항체 및 면역접합체
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカAcademia Sinica |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
WO2015184203A1
(en)
|
2014-05-29 |
2015-12-03 |
Macrogenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
HUE055189T2
(hu)
|
2014-06-04 |
2021-11-29 |
Biontech Res And Development Inc |
Humán monoklonális antitestek a GD2 ganglioziddal ellen
|
KR101923326B1
(ko)
|
2014-06-06 |
2018-11-29 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
WO2015191760A2
(en)
|
2014-06-10 |
2015-12-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
US20160002343A1
(en)
|
2014-06-11 |
2016-01-07 |
Abbvie Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3160991A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Zusammensetzungen und verfahren für proteine mit langer wirkung
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3160478A4
(de)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-ix-gen
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
WO2016007775A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
AU2015288232B2
(en)
|
2014-07-11 |
2020-10-15 |
Ventana Medical Systems, Inc. |
Anti-PD-L1 antibodies and diagnostic uses thereof
|
RU2739952C2
(ru)
|
2014-07-15 |
2020-12-30 |
МЕДИММЬЮН, ЭлЭлСи |
Нейтрализующие антитела к вирусу гриппа b и пути их применения
|
AU2015292678B2
(en)
|
2014-07-22 |
2020-10-22 |
Cb Therapeutics, Inc. |
Anti-PD-1 antibodies
|
US20170348402A1
(en)
|
2014-07-30 |
2017-12-07 |
The Research Foundation For The State University Of New York |
System and method for delivering genetic material or protein to cells
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
AU2015295986B2
(en)
|
2014-08-01 |
2018-11-08 |
Massachusetts Institute Of Technology |
Modified alginates for anti-fibrotic materials and applications
|
EP2982692A1
(de)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispezifische Antikörper gegen CD3-Epsilon und BCMA
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
CA2956399A1
(en)
|
2014-08-05 |
2016-02-11 |
Cb Therapeutics, Inc. |
Anti-pd-l1 antibodies
|
CN107148428B
(zh)
|
2014-08-07 |
2021-03-09 |
诺华股份有限公司 |
血管生成素样蛋白4抗体和使用方法
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
WO2016024195A1
(en)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
EP3070102A1
(de)
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von antikörpern zur aktivierung des menschlichem cd40 und antikörpern gegen menschliches pd-l1
|
JP6586454B2
(ja)
|
2014-08-14 |
2019-10-02 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトcd40を活性化する抗体とヒトpd−l1に対する抗体との併用療法
|
CN107148430B
(zh)
|
2014-08-19 |
2021-08-27 |
默沙东公司 |
抗tigit抗体
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
EP4074735A1
(de)
|
2014-08-28 |
2022-10-19 |
BioAtla, Inc. |
Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
|
KR102523914B1
(ko)
|
2014-09-03 |
2023-04-19 |
베링거잉겔하임인터내쇼날유한회사 |
Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
PE20170935A1
(es)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
SG10201804931QA
(en)
|
2014-09-12 |
2018-07-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
CA2959428A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
MX2017003897A
(es)
|
2014-09-26 |
2017-06-28 |
Bayer Pharma AG |
Derivados estabilizados de adrenomedulina y uso de los mismos.
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
BR112017005988A2
(pt)
|
2014-09-26 |
2017-12-19 |
Macrogenics Inc |
diacorpo de fc monovalente biespecífico cd19 x cd3 capaz de realizar ligação específica a cd19 e a cd3, complexo polipeptídico covalentemente associado, composição farmacêutica, e uso da composição farmacêutica
|
EP3201227A4
(de)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016055592A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
EP3799887A1
(de)
|
2014-10-09 |
2021-04-07 |
Genzyme Corporation |
Durch glycoengineering hergestellte antikörperarzneimittelkonjugate
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
MA41480A
(fr)
|
2014-10-17 |
2017-12-19 |
Glenmark Pharmaceuticals Sa |
Anticorps qui se lient au ccr6 et leurs utilisations
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
JP6687612B2
(ja)
|
2014-10-24 |
2020-04-22 |
アストラゼネカ アクチボラグ |
組合せ
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
BR112017009159A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
|
MX2017005930A
(es)
|
2014-11-05 |
2017-06-30 |
Genentech Inc |
Metodo de produccion de proteinas de cadena doble en bacterias.
|
WO2016073794A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
US10208120B2
(en)
|
2014-11-05 |
2019-02-19 |
Genentech, Inc. |
Anti-FGFR2/3 antibodies and methods using same
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
RS59340B1
(sr)
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
WO2016075099A1
(en)
|
2014-11-10 |
2016-05-19 |
Medimmune Limited |
Binding molecules specific for cd73 and uses thereof
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン−33抗体及びその使用
|
US20160129108A1
(en)
|
2014-11-11 |
2016-05-12 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
|
CN108064244B
(zh)
|
2014-11-14 |
2021-09-17 |
诺华股份有限公司 |
抗体药物缀合物
|
EP3221360A1
(de)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
DK3221359T3
(da)
|
2014-11-17 |
2020-06-22 |
Regeneron Pharma |
Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
|
EP3221361B1
(de)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
PL3221349T3
(pl)
|
2014-11-19 |
2021-05-17 |
Axon Neuroscience Se |
Humanizowane przeciwciała tau w chorobie Alzheimera
|
EP3221364B1
(de)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
|
EP3023437A1
(de)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispezifische Antikörper gegen CD3epsilon und BCMA
|
MX2017006323A
(es)
|
2014-11-21 |
2017-08-21 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
EP3581585A1
(de)
|
2014-11-26 |
2019-12-18 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab zur behandlung von fistelbildendem morbus crohn
|
EP3029068A1
(de)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispezifische Antikörper gegen CD3-Epsilon-BCMA und zur Verwendung bei der Behandlung von Krankheiten
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
CN107108739B
(zh)
|
2014-12-05 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
抗CD79b抗体和使用方法
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
EP3229836B1
(de)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Menschliche monoklonale antikörper gegen axl
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
SI3233921T1
(sl)
|
2014-12-19 |
2022-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelesa proti C5 in postopki za uporabo
|
ES2881346T3
(es)
|
2014-12-19 |
2021-11-29 |
Regenesance B V |
Anticuerpos que se unen a C6 humano y usos de los mismos
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
EP3237906B8
(de)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
|
SG11201705063VA
(en)
|
2014-12-23 |
2017-07-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗lapモノクローナル抗体による癌の処置
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
US10342858B2
(en)
|
2015-01-24 |
2019-07-09 |
Academia Sinica |
Glycan conjugates and methods of use thereof
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
CA2974715C
(en)
|
2015-01-27 |
2020-05-05 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
TWI769570B
(zh)
|
2015-01-28 |
2022-07-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
TWI718121B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
TWI718122B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
KR20170110129A
(ko)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
EP3978929A1
(de)
|
2015-02-19 |
2022-04-06 |
Compugen Ltd. |
Pvrig-polypeptide und verfahren zur behandlung
|
PT3258951T
(pt)
|
2015-02-19 |
2020-08-18 |
Compugen Ltd |
Anticorpos anti-pvrig e métodos de utilização
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
SG10201907901XA
(en)
|
2015-03-03 |
2019-10-30 |
Kymab Ltd |
Antibodies, uses & methods
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
AU2016230827B2
(en)
|
2015-03-09 |
2021-10-28 |
Argenx Bvba |
Methods of reducing serum levels of fc-containing agents using fcrn antagonists
|
WO2016145307A1
(en)
|
2015-03-12 |
2016-09-15 |
Medimmune, Llc |
Method of purifying albumin-fusion proteins
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
US10722592B2
(en)
|
2015-03-18 |
2020-07-28 |
Seattle Genetics, Inc. |
CD48 antibodies and conjugates thereof
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
US10556952B2
(en)
|
2015-03-30 |
2020-02-11 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to Fc gamma receptors
|
MY186708A
(en)
|
2015-04-03 |
2021-08-11 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
CA2982246A1
(en)
|
2015-04-17 |
2016-10-20 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
FI3283524T3
(fi)
|
2015-04-17 |
2023-05-05 |
Amgen Res Munich Gmbh |
Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle
|
EP3878857A1
(de)
|
2015-04-22 |
2021-09-15 |
Biogen MA Inc. |
Neuartige hybride actriib-liganden-trap-proteine zur behandlung von muskelschwunderkrankungen
|
EP3286315B1
(de)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
|
EP3288976B1
(de)
|
2015-04-29 |
2020-04-08 |
Regeneron Pharmaceuticals, Inc. |
Behandlung von fibrodysplasia ossificans progressiva
|
EP3288981A1
(de)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Maskierte anti-cd3-antikörper und verfahren zur verwendung
|
EA201792451A1
(ru)
|
2015-05-07 |
2018-05-31 |
Агенус Инк. |
Антитела к ox40 и способы их применения
|
EP3936524A3
(de)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
SI3294770T1
(sl)
|
2015-05-12 |
2021-01-29 |
F. Hoffmann-La Roche Ag |
Terapevtski in diagnostični postopki za raka
|
WO2016188911A1
(en)
|
2015-05-22 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
CR20170592A
(es)
|
2015-05-29 |
2018-02-13 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
EP3303384B1
(de)
|
2015-06-01 |
2021-08-25 |
Medimmune, LLC |
Neutralisierende anti-influeanza-bindungsmoleküle und verwendungen davon
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
MX2017015260A
(es)
|
2015-06-03 |
2018-02-19 |
Squibb Bristol Myers Co |
Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
|
WO2016197071A1
(en)
|
2015-06-05 |
2016-12-08 |
New York University |
Compositions and methods for anti-staphylococcal biologic agents
|
MX2017015690A
(es)
|
2015-06-05 |
2018-07-06 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
|
SG10201911349YA
(en)
|
2015-06-05 |
2020-01-30 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Cd123抗體及其共軛物
|
US11820807B2
(en)
|
2015-06-12 |
2023-11-21 |
Ubi Pharma Inc |
Immunoglobulin fusion proteins and uses thereof
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
LT3310814T
(lt)
|
2015-06-16 |
2023-10-10 |
F. Hoffmann-La Roche Ag |
Humanizuoti ir subrendusio giminingumo antikūnai prieš fcrh5 ir jų naudojimo būdai
|
EP3310813A1
(de)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antikörper-wirkstoff-konjugate
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
MX2017016169A
(es)
|
2015-06-17 |
2018-08-15 |
Genentech Inc |
Anticuerpos anti-her2 y metodos de uso.
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
EP3108897A1
(de)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antikörper gegen menschliches csf-1r für die induzierung von lymphozytose in lymphomen oder leukämien
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
ES2908009T3
(es)
|
2015-06-24 |
2022-04-27 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad adaptada
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
ES2898065T3
(es)
|
2015-06-29 |
2022-03-03 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
|
MX2017017049A
(es)
|
2015-06-30 |
2018-03-06 |
Seattle Genetics Inc |
Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.
|
EP3322733B1
(de)
|
2015-07-13 |
2021-09-15 |
Compugen Ltd. |
Hide1-zusammensetzungen und verfahren
|
EP3325010B1
(de)
|
2015-07-23 |
2023-06-21 |
The Regents of The University of California |
Antikörper gegen gerinnungsfaktor xia und verwendungen davon
|
PT3325011T
(pt)
*
|
2015-07-24 |
2021-01-27 |
Gliknik Inc |
Proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadamente com ligação a complemento melhorada
|
EP3317301B1
(de)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen lag-3
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
HRP20211645T1
(hr)
|
2015-07-30 |
2022-02-04 |
Macrogenics, Inc. |
Molekule za vezanje pd-1 i postupci za njihovu uporabu
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
DK3331910T3
(da)
|
2015-08-03 |
2020-03-16 |
Engmab Sarl |
Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)
|
MX2018001497A
(es)
|
2015-08-03 |
2018-05-15 |
Bioverativ Therapeutics Inc |
Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
|
RU2752530C2
(ru)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Способы лечения расстройств, связанных с fgf21
|
KR20180035884A
(ko)
|
2015-08-04 |
2018-04-06 |
악셀레론 파마 인코포레이티드 |
골수증식성 장애를 치료하기 위한 방법
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
PT3347377T
(pt)
|
2015-09-09 |
2021-04-30 |
Novartis Ag |
Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
CA2998716A1
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
GB2558131B
(en)
|
2015-09-21 |
2021-05-19 |
Surface Oncology Inc |
Anti-CD47 antibodies and methods of use
|
CA2999369C
(en)
|
2015-09-22 |
2023-11-07 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Improved variants of anti-VEGF antibodies
|
EP3662930A1
(de)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv-antikörperzusammensetzungen und verfahren zur verwendung
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
CA2997799A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-pd1 antibodies and methods of use
|
EP3150636A1
(de)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalente multispezifische antikörper
|
CR20180171A
(es)
|
2015-10-07 |
2018-05-03 |
Hoffmann La Roche |
Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
MX2018005036A
(es)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
CN115160439A
(zh)
|
2015-10-30 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
抗-HtrA1抗体及其使用方法
|
US10941204B2
(en)
|
2015-10-30 |
2021-03-09 |
Galaxy Biotech, Llc |
Highly potent antibodies binding to death receptor 4
|
EP3368074A2
(de)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-faktor-d-antikörper und -konjugate
|
MX2018005420A
(es)
|
2015-11-01 |
2018-06-06 |
Massachusetts Inst Technology |
Alginatos modificados para materiales anti-fibroticos y aplicaciones.
|
EP3371349A1
(de)
|
2015-11-02 |
2018-09-12 |
Bioatla, LLC |
Bedingt aktive polypeptide
|
MX2018005550A
(es)
|
2015-11-03 |
2019-07-18 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a tim-3 y sus usos.
|
EP3371217A1
(de)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Screening-verfahren für multispezifische antikörper
|
AU2016353073A1
(en)
|
2015-11-10 |
2018-06-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
|
EP3378487B1
(de)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Kombinationstherapie mit t-zell-neuausrichtendem antigenbindendem molekül gegen zelle mit immunsuppressiver funktion
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
WO2017085693A1
(en)
|
2015-11-19 |
2017-05-26 |
AbbVie Deutschland GmbH & Co. KG |
Reporter gene assay methods for identifying and analyzing multi-specific binding proteins
|
JP6983776B2
(ja)
|
2015-11-19 |
2021-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
グルココルチコイド誘発腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
|
LT3380522T
(lt)
|
2015-11-25 |
2024-02-26 |
Visterra, Inc. |
Antikūnai prieš april molekules ir jų panaudojimas
|
JP6849694B2
(ja)
|
2015-11-30 |
2021-03-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
抗ヒトip−10抗体およびそれらの使用
|
BR112018008789A2
(pt)
|
2015-11-30 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
método para a determinação da quantidade de um anticorpo bivalente em uma amostra de soro ou plasma
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
EP3383430A4
(de)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
Antikörper und verfahren zur verwendung davon
|
UY37003A
(es)
|
2015-12-04 |
2017-06-30 |
Novartis Ag |
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
|
MX2018007089A
(es)
|
2015-12-14 |
2019-01-30 |
Macrogenics Inc |
Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
|
US11045547B2
(en)
|
2015-12-16 |
2021-06-29 |
Merck Sharp & Dohme Corp. |
Anti-LAG3 antibodies and antigen-binding fragments
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
PD−1に対する抗体分子とC−Met阻害剤との組合せおよびその使用
|
JP2019502698A
(ja)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク,インコーポレーテツド |
Hla−drに特異的に結合する抗体及びその使用
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
EA038551B1
(ru)
|
2015-12-17 |
2021-09-14 |
Дзе Джонс Хопкинс Юниверсити |
Способ лечения или профилактики системного склероза
|
EP3389711A1
(de)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Auf cd32b gerichtete antikörper und verfahren zur verwendung davon
|
AU2016372930B2
(en)
|
2015-12-18 |
2020-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies and methods of use
|
WO2017112954A1
(en)
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
EP3398965A4
(de)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
|
EP3397276A4
(de)
|
2015-12-30 |
2019-12-18 |
Kodiak Sciences Inc. |
Antikörper und konjugate davon
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
BR112018014762A2
(pt)
|
2016-01-20 |
2018-12-26 |
Genentech Inc |
método de tratamento da doença de alzheimer (da) precoce
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
WO2017132103A2
(en)
|
2016-01-29 |
2017-08-03 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
RS63548B1
(sr)
|
2016-02-01 |
2022-09-30 |
Bioverativ Therapeutics Inc |
Optimizovani geni faktora viii
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
FI3411404T3
(fi)
|
2016-02-03 |
2023-01-31 |
|
T-soluja aktivoivia psma- ja cd3-bispesifisisiä vasta-ainekonstrukteja
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
AU2017219254B2
(en)
|
2016-02-17 |
2019-12-12 |
Novartis Ag |
TGFbeta 2 antibodies
|
SG10202007836WA
(en)
|
2016-02-17 |
2020-09-29 |
Seattle Genetics Inc |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
EP3430052A2
(de)
|
2016-03-14 |
2019-01-23 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur vorbeugung der transplantat-wirt-krankheit
|
CA3017758A1
(en)
|
2016-03-14 |
2017-09-21 |
Millennium Pharmaceuticals, Inc. |
Methods of treating or preventing graft versus host disease
|
TW202214700A
(zh)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
CA3017622A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc. |
Engineered trail for cancer therapy
|
KR102464372B1
(ko)
|
2016-03-17 |
2022-11-04 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
EP3433281A1
(de)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispezifische und multifunktionelle moleküle und verwendungen davon
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
KR102640157B1
(ko)
|
2016-03-22 |
2024-02-27 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
인간화 항-클라우딘-1 항체 및 이의 용도
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
MA44483A
(fr)
|
2016-03-24 |
2019-01-30 |
Millennium Pharm Inc |
Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
|
CA3018216A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulations of antibody molecules to dengue virus
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
CN114456176A
(zh)
|
2016-03-28 |
2022-05-10 |
因赛特公司 |
作为tam抑制剂的吡咯并三嗪化合物
|
CN109195620B
(zh)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
|
EP3443004A1
(de)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3-antikörper und verfahren zur verwendung
|
KR20190006495A
(ko)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
EP3443120A2
(de)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
EP3442562B1
(de)
|
2016-04-15 |
2022-09-21 |
Evive Biotechnology (Shanghai) Ltd |
Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
|
US20210017281A1
(en)
|
2016-04-15 |
2021-01-21 |
Immunext, Inc. |
Anti-human vista antibodies and use thereof
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
KR20230051602A
(ko)
|
2016-04-15 |
2023-04-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
EP3448997B1
(de)
|
2016-04-27 |
2020-10-14 |
Massachusetts Institute of Technology |
Stabile nanoskalige nukleinsäureanordnungen und verfahren dafür
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
BR112018071276A2
(pt)
|
2016-04-27 |
2019-02-12 |
Pfizer Inc. |
anticorpos anti-il-33, composições, métodos e usos dos mesmos
|
PE20190261A1
(es)
|
2016-05-02 |
2019-02-25 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
CA3022765A1
(en)
|
2016-05-02 |
2017-11-09 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
MA56474A
(fr)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
Contorsbody - liant de cible à chaîne unique
|
PL3452507T3
(pl)
|
2016-05-02 |
2023-01-09 |
Prothena Biosciences Limited |
Immunoterapia tau
|
EA039084B1
(ru)
|
2016-05-09 |
2021-12-01 |
Бристол-Майерс Сквибб Компани |
Антитела к tl1a и их применения
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
LT3458478T
(lt)
|
2016-05-18 |
2021-02-10 |
Boehringer Ingelheim International Gmbh |
Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui
|
EP3458101B1
(de)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac-antikörper-konjugate und verfahren zur verwendung
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
WO2017210586A1
(en)
|
2016-06-03 |
2017-12-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
MX2018015277A
(es)
|
2016-06-08 |
2019-09-06 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
|
EP3888689A1
(de)
|
2016-06-08 |
2021-10-06 |
AbbVie Inc. |
Anti-egfr-antikörper-wirkstoff-konjugate
|
US20200121803A1
(en)
|
2016-06-08 |
2020-04-23 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
RU2764651C2
(ru)
|
2016-06-08 |
2022-01-19 |
Эббви Инк. |
Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
|
TW201808987A
(zh)
|
2016-06-08 |
2018-03-16 |
健生生物科技公司 |
Gm-csf變體及使用方法
|
EP3468598A1
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörper-wirkstoff-konjugate
|
AU2017279554A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
CN109562168A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CN109562190A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
CA3027178A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
WO2017218434A1
(en)
|
2016-06-12 |
2017-12-21 |
Millennium Pharmaceuticals, Inc. |
Method of treating inflammatory bowel disease
|
CA3027651A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
CN116143918A
(zh)
|
2016-06-24 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
WO2018007923A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
EP3478716A2
(de)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin-antikörper
|
JP7076711B2
(ja)
|
2016-07-02 |
2022-05-30 |
プロセナ バイオサイエンシーズ リミテッド |
抗トランスサイレチン抗体
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
US11306143B2
(en)
|
2016-07-06 |
2022-04-19 |
Bristol-Myers Squibb Company |
Combination of TIM-4 antagonist and PD-1 antagonist and methods of use
|
JP7011764B2
(ja)
|
2016-07-07 |
2022-01-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
抗体アジュバント複合体
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487880A1
(de)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5(grp78)-antikörper und verwendungen davon
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
KR102553195B1
(ko)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
JP7219207B2
(ja)
|
2016-07-29 |
2023-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
腫瘍関連マクロファージを標的化する抗体及びその使用
|
EP3490600A1
(de)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
|
EP3494134A1
(de)
|
2016-08-02 |
2019-06-12 |
Visterra, Inc. |
Manipulierte polypeptide und verwendungen davon
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
MX2019001471A
(es)
|
2016-08-05 |
2019-10-30 |
Allakos Inc |
Anticuerpos anti-siglec-7 para el tratamiento del cancer.
|
BR112019002039A2
(pt)
|
2016-08-05 |
2019-05-07 |
Medimmune, Llc |
anticorpos anti-o2 e uso dos mesmos
|
EP3494991A4
(de)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
CN110267977A
(zh)
|
2016-08-10 |
2019-09-20 |
亚洲大学校产学协力团 |
细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
|
EP3496763A1
(de)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
US20180044430A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
|
AU2017313085A1
(en)
|
2016-08-19 |
2019-03-14 |
Beigene Switzerland Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
US20190270821A1
(en)
|
2016-09-13 |
2019-09-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
BR112019005001A2
(pt)
|
2016-09-15 |
2019-06-04 |
Univ Stuttgart |
proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
EP3515932B1
(de)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Auf komplementfaktor basierende affinitätschromatographie
|
EP3515478B1
(de)
|
2016-09-21 |
2024-02-28 |
Nextcure, Inc. |
Antikörper für siglec-15 und verfahren zur verwendung davon
|
SI3528838T1
(sl)
|
2016-09-23 |
2023-10-30 |
F. Hoffmann-La Roche Ag |
Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa
|
AU2017331277A1
(en)
|
2016-09-23 |
2019-03-28 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3518969A2
(de)
|
2016-09-28 |
2019-08-07 |
Xoma (Us) Llc |
Antikörper zur bindung von interleukin-2 und verwendungen davon
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
TWI775781B
(zh)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
癌症之治療性及診斷性方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526256A1
(de)
|
2016-10-11 |
2019-08-21 |
Agenus Inc. |
Anti-lag-3-antikörper und verfahren zur verwendung davon
|
CN109952370B
(zh)
|
2016-10-19 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
用于产生免疫缀合物的方法
|
BR112019007147A2
(pt)
|
2016-10-19 |
2019-06-25 |
Humabs Biomed Sa |
anticorpos anti-o1 e usos dos mesmos
|
US10322174B2
(en)
|
2016-10-26 |
2019-06-18 |
Cedars-Sinai Medical Center |
Neutralizing anti-TL1A monoclonal antibodies
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
KR20190086477A
(ko)
|
2016-11-02 |
2019-07-22 |
잉맵 에스에이알엘 |
다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
AU2017361081A1
(en)
|
2016-11-15 |
2019-05-23 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
EP4015532A1
(de)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73-antikörper und immunkonjugate
|
CN108367075B
(zh)
|
2016-11-23 |
2022-08-09 |
免疫方舟医药技术股份有限公司 |
4-1bb结合蛋白及其用途
|
TN2019000164A1
(en)
|
2016-11-23 |
2020-10-05 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
EP3548063A1
(de)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Verfahren zur induktion von immuntoleranz gegenüber gerinnungsfaktoren
|
IL266972B2
(en)
|
2016-12-02 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
AU2017373884A1
(en)
|
2016-12-07 |
2019-05-30 |
Ac Immune Sa |
Anti-tau antibodies and methods of their use
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
AU2017373889A1
(en)
|
2016-12-07 |
2019-06-06 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
KR20190095921A
(ko)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
WO2018112108A1
(en)
|
2016-12-13 |
2018-06-21 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
AU2017381585A1
(en)
|
2016-12-19 |
2019-07-18 |
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats |
Antibodies against LIF and uses thereof
|
WO2018115960A1
(en)
|
2016-12-19 |
2018-06-28 |
Mosaic Biomedicals, S.L. |
Antibodies against lif and uses thereof
|
WO2018114728A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
|
CA3039446A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
WO2018114877A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
BR112019010294A2
(pt)
|
2016-12-21 |
2019-09-03 |
Hoffmann La Roche |
método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
|
EP3559250A1
(de)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Wiederverwendung von enzymen im in-vitro-glyco-engineering von antikörpern
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
KR20190111036A
(ko)
|
2016-12-23 |
2019-10-01 |
비스테라, 인크. |
결합 폴리펩타이드 및 이의 제조 방법
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
JP7110199B2
(ja)
|
2016-12-23 |
2022-08-01 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体による処置法
|
MX2019007795A
(es)
|
2017-01-03 |
2019-08-16 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
TW201833140A
(zh)
|
2017-01-09 |
2018-09-16 |
美商莫瑞麥克製藥公司 |
抗fgfr抗體及使用方法
|
EP3568468A4
(de)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
Gegen histon-h3-peptid/mhc-komplexe gerichtete konstrukte und verwendungen davon
|
CA3049449A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
EP3573989A4
(de)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
Kristalline formen von (s)-7-(1-(but-2-ynoyl)-piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-carboxamid, herstellung und verwendungen davon
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
JP6383122B2
(ja)
|
2017-01-31 |
2018-08-29 |
中外製薬株式会社 |
C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
CA3051700A1
(en)
|
2017-02-10 |
2018-08-16 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018151821A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
US10765762B2
(en)
|
2017-02-27 |
2020-09-08 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
EP3589320A4
(de)
|
2017-02-28 |
2020-12-23 |
Seagen Inc. |
Cysteinmutierte antikörper für konjugation
|
CN110546277A
(zh)
|
2017-03-01 |
2019-12-06 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
MX2019010575A
(es)
|
2017-03-10 |
2019-10-15 |
Hoffmann La Roche |
Metodo para producir anticuerpos multiespecificos.
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Pd−l2バリアント免疫調節タンパク質及びその使用
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
CN110831963A
(zh)
|
2017-03-16 |
2020-02-21 |
高山免疫科学股份有限公司 |
Pd-l1变体免疫调节蛋白及其用途
|
EP3600442A1
(de)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimierte antikörperzusammensetzungen zur behandlung von augenkrankheiten
|
AU2018240117A1
(en)
|
2017-03-24 |
2019-09-19 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for preventing and treating heart disease
|
EP3601337A1
(de)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Verfahren zur behandlung neurodegenerativer erkrankungen
|
EP3601346A1
(de)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体のための二重特異性抗原結合分子
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
JP2020515637A
(ja)
|
2017-04-03 |
2020-05-28 |
オンコロジー、インコーポレイテッド |
免疫腫瘍剤を伴うps標的化抗体を用いる癌の治療方法
|
CR20190427A
(es)
|
2017-04-04 |
2019-11-01 |
Hoffmann La Roche |
Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap
|
CN110392698B
(zh)
|
2017-04-05 |
2022-01-25 |
豪夫迈·罗氏有限公司 |
抗lag3抗体
|
JP6997212B2
(ja)
|
2017-04-05 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1及びlag3に特異的に結合する二重特異性抗体
|
US11634495B2
(en)
|
2017-04-07 |
2023-04-25 |
Miltenyi Biotec B.V. & Co. KG |
Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
ES2957464T3
(es)
|
2017-04-14 |
2024-01-19 |
Univ Arizona |
Composiciones y métodos para tratar fibrosis pulmonar
|
CA3058478A1
(en)
|
2017-04-14 |
2018-10-18 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
EP3609540B1
(de)
|
2017-04-14 |
2023-01-11 |
Bolt Biotherapeutics, Inc. |
Verfahren zur immunkonjugatsynthese
|
EP3612563A1
(de)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
EP3612215A4
(de)
|
2017-04-20 |
2021-05-26 |
aTyr Pharma, Inc. |
Zusammensetzungen und verfahren zur behandlung von lungenentzündungen
|
CA3059615A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
KR20200012860A
(ko)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
US20200179486A1
(en)
|
2017-04-28 |
2020-06-11 |
Millennium Pharmaceuticals, Inc. |
Method of treating pediatric disorders
|
EP3615566B1
(de)
|
2017-04-28 |
2023-12-20 |
Marengo Therapeutics, Inc. |
Multispezifische moleküle mit einem nicht-immunoglobulin-heterodimerisazionsbereich
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
ES2952961T3
(es)
|
2017-05-01 |
2023-11-07 |
Agenus Inc |
Anticuerpos anti-TIGIT y métodos de uso de los mismos
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
KR102635723B1
(ko)
|
2017-05-04 |
2024-02-08 |
악셀레론 파마 인코포레이티드 |
Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
|
EA201992626A1
(ru)
|
2017-05-05 |
2020-04-24 |
Аллакос Инк. |
Способы и композиции для лечения аллергических заболеваний глаз
|
EP3618864A1
(de)
|
2017-05-05 |
2020-03-11 |
Amgen Inc. |
Pharmazeutische zusammensetzung mit bispezifischen antikörperkonstrukten zur verbesserten aufbewahrung und verabreichung
|
EP3635391A4
(de)
|
2017-05-08 |
2021-06-02 |
Majed El-Dweik |
Vorrichtung und verfahren zur detektion von mikrobieller verunreinigung
|
BR112019023409A2
(pt)
|
2017-05-10 |
2020-06-16 |
Iovance Biotherapeutics, Inc. |
Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
CA3061235A1
(en)
|
2017-05-18 |
2018-11-22 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
US20200270334A1
(en)
|
2017-05-24 |
2020-08-27 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
AU2018272852A1
(en)
|
2017-05-25 |
2019-11-28 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
AU2018276140A1
(en)
|
2017-06-01 |
2019-12-19 |
Compugen Ltd. |
Triple combination antibody therapies
|
TW201902462A
(zh)
|
2017-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
用於免疫促效劑之新穎投與途徑
|
WO2018220169A1
(en)
|
2017-06-02 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
EP3418302A1
(de)
|
2017-06-19 |
2018-12-26 |
F. Hoffmann-La Roche AG |
Verabreichungswege für immunagonisten
|
EP3635007A1
(de)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
US11851651B2
(en)
|
2017-06-19 |
2023-12-26 |
Massachusetts Institute Of Technology |
Automated methods for scalable, parallelized enzymatic biopolymer synthesis and modification using microfluidic devices
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
PE20200013A1
(es)
|
2017-06-20 |
2020-01-06 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
JP2020525434A
(ja)
|
2017-06-22 |
2020-08-27 |
ムーンショット ファーマ エルエルシー |
アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP7433910B2
(ja)
|
2017-06-22 |
2024-02-20 |
ノバルティス アーゲー |
Cd73に対する抗体分子及びその使用
|
CN111587124B
(zh)
|
2017-06-23 |
2024-01-12 |
维洛斯生物股份有限公司 |
Ror1抗体免疫缀合物
|
EP3645569A4
(de)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
Immuntherapie für leberzellkarzinom
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
JP2020527351A
(ja)
|
2017-07-21 |
2020-09-10 |
ジェネンテック, インコーポレイテッド |
がんの治療法及び診断法
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
AU2018308364C1
(en)
|
2017-07-26 |
2023-02-16 |
Forty Seven, Inc. |
Anti-SIRP-alpha antibodies and related methods
|
TWI818916B
(zh)
|
2017-07-27 |
2023-10-21 |
日商第一三共股份有限公司 |
抗cd147抗體、及其用途與製造方法
|
AU2018306612C1
(en)
|
2017-07-27 |
2023-11-09 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-C5 antibody formulations
|
CN117050176A
(zh)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
基于三维结构的人源化方法
|
WO2019032898A1
(en)
|
2017-08-09 |
2019-02-14 |
Bioverativ Therapeutics Inc. |
NUCLEIC ACID MOLECULES AND USES THEREOF
|
EP3665197A2
(de)
|
2017-08-11 |
2020-06-17 |
H. Hoffnabb-La Roche Ag |
Anti-cd8-antikörper und verwendungen davon
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
KR20200039778A
(ko)
|
2017-08-22 |
2020-04-16 |
사나바이오, 엘엘씨 |
가용성 인터페론 수용체 및 그의 용도
|
WO2019040780A1
(en)
|
2017-08-25 |
2019-02-28 |
Five Prime Therapeutics Inc. |
ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
|
MX2020002241A
(es)
|
2017-08-28 |
2020-09-03 |
Angiex Inc |
Anticuerpos anti-tm4sf y métodos de uso de los mismos.
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
WO2019064053A1
(en)
|
2017-09-28 |
2019-04-04 |
Prothena Biosciences Limited |
DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
US20200239559A1
(en)
|
2017-09-29 |
2020-07-30 |
Boehringer Ingelheim International Gmbh |
Anti igf, anti pd-1, anti-cancer combination therapy
|
RU2020109412A
(ru)
|
2017-09-29 |
2021-10-29 |
Даити Санкио Компани, Лимитед |
Конъюгат антитело-производное пирролобензодиазепина
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
EP3692069A1
(de)
|
2017-10-02 |
2020-08-12 |
Visterra, Inc. |
Antikörpermoleküle gegen cd138 und verwendungen davon
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
CA3198255A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
EP3694890A4
(de)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
Leichtkettiges antikörperfusionsprotein mit vegfr
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
US11472889B2
(en)
|
2017-10-14 |
2022-10-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
MA50404A
(fr)
|
2017-10-18 |
2020-08-26 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
|
KR20200072507A
(ko)
|
2017-10-19 |
2020-06-22 |
데비오팜 인터네셔날 에스 에이 |
암 치료를 위한 조합 제품
|
CA3078157A1
(en)
|
2017-10-20 |
2019-04-25 |
F.Hoffmann-La Roche Ag |
Method for generating multispecific antibodies from monospecific antibodies
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
BR112020008031A2
(pt)
|
2017-11-01 |
2020-10-27 |
F. Hoffmann-La Roche Ag |
anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
|
EP3704150A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Compbody ein multivalentes zielbindemittel
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
US10940171B2
(en)
|
2017-11-10 |
2021-03-09 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CN111902427A
(zh)
|
2017-11-22 |
2020-11-06 |
诺华股份有限公司 |
抗因子XI/XIa抗体的逆转结合剂及其用途
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
WO2019106578A2
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
MA51032A
(fr)
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性分子及びその使用
|
SG11202004273YA
(en)
|
2017-12-11 |
2020-06-29 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
IL275427B2
(en)
|
2017-12-19 |
2024-04-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis virus vaccines HBV) B) and their uses
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
US20210087267A1
(en)
|
2017-12-20 |
2021-03-25 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN115925943A
(zh)
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
EP3732202A4
(de)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
Einzeldomänenantikörper und varianten davon gegen tigit
|
US20220135687A1
(en)
|
2017-12-28 |
2022-05-05 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
KR20200106525A
(ko)
|
2018-01-05 |
2020-09-14 |
에이씨 이뮨 에스.에이. |
미스폴딩된 tdp-43 결합 분자
|
EP3508499A1
(de)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antikörper zum targeting von, und andere modulatoren von, einem immunglobulingen im zusammenhang mit resistenz gegen antitumor-immunantworten und verwendungen davon
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
CN112566934A
(zh)
|
2018-01-23 |
2021-03-26 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
US20210251899A1
(en)
|
2018-01-25 |
2021-08-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
ES2932861T3
(es)
|
2018-01-26 |
2023-01-27 |
Hoffmann La Roche |
Composiciones de IL-22 Fc y procedimientos de uso
|
CR20200327A
(es)
|
2018-01-26 |
2020-11-05 |
Genentech Inc |
Proteínas de fusión fc il-22 y métodos de uso
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
AU2019215063A1
(en)
|
2018-02-01 |
2020-09-03 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing Factor VIII
|
CN111868082A
(zh)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
调节vista和vsig3的相互作用的化合物及其制备和使用方法
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
KR102417088B1
(ko)
|
2018-02-09 |
2022-07-07 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
EP3752530A1
(de)
|
2018-02-14 |
2020-12-23 |
ABBA Therapeutics AG |
Anti-human-pd-l1-antikörper
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
JP2021513978A
(ja)
|
2018-02-16 |
2021-06-03 |
アッヴィ・インコーポレイテッド |
がん治療における選択的bcl−2阻害剤及び抗pd−1抗体又は抗pd−l1抗体の併用
|
EP3755364A1
(de)
|
2018-02-21 |
2020-12-30 |
F. Hoffmann-La Roche AG |
Dosierung zur behandlung mit il-22-fc-fusionsproteinen
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
CA3092470A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
JP2021516051A
(ja)
|
2018-03-02 |
2021-07-01 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
B7−h4抗体及びその使用方法
|
EP3763386A4
(de)
|
2018-03-05 |
2021-12-29 |
Saitama Medical University |
Pharmazeutische zusammensetzung zur behandlung oder vorbeugung von heterotoper ossifikation
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
EP3765516A2
(de)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunktionale moleküle und verwendungen davon
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
TW202003553A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療癌症之abbv-621與抗癌劑之組合
|
WO2019178433A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
WO2019179365A1
(en)
|
2018-03-20 |
2019-09-26 |
WuXi Biologics Ireland Limited |
Novel anti-lag-3 antibody polypeptide
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
BR112020018918A2
(pt)
|
2018-03-22 |
2021-01-05 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
CA3093850A1
(en)
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
PL3775909T3
(pl)
|
2018-03-26 |
2023-09-18 |
Glycanostics S.R.O. |
Środki i sposoby do profilowania glikozylacji białka
|
KR20200144551A
(ko)
|
2018-03-28 |
2020-12-29 |
악손 뉴로사이언스 에스이 |
알츠하이머병을 검출하고 치료하는 항체-기반 방법
|
TW202003551A
(zh)
|
2018-03-28 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
AU2019245243A1
(en)
|
2018-03-29 |
2020-09-03 |
Genentech, Inc |
Modulating lactogenic activity in mammalian cells
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
EP3774916A2
(de)
|
2018-04-06 |
2021-02-17 |
Biolegend, Inc. |
Anti-tetraspanin-33-wirkstoffe und -zusammensetzungen und verfahren zur herstellung und verwendung davon
|
EP3552631A1
(de)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
|
EP3774895A1
(de)
|
2018-04-12 |
2021-02-17 |
MedImmune Limited |
Kombination von lif-inhibitoren und pd-1-achsen-inhibitoren zur verwendung bei der behandlung von krebs
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
CA3098096A1
(en)
|
2018-04-24 |
2019-10-31 |
Ampsource Biopharma Shanghai Inc. |
Antibody against tim-3 and application thereof
|
CA3098374A1
(en)
|
2018-04-25 |
2019-10-31 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
CN112041333A
(zh)
|
2018-04-26 |
2020-12-04 |
古德T细胞有限公司 |
新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物
|
SG11202010388SA
(en)
|
2018-04-30 |
2020-11-27 |
Takeda Pharmaceuticals Co |
Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
|
EP3787678A1
(de)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Monoklonale neuraminidase-antikörper gegen influenza und ihre verwendungen
|
CN110464842B
(zh)
|
2018-05-11 |
2022-10-14 |
信达生物制药(苏州)有限公司 |
包含抗pcsk9抗体的制剂及其用途
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
CN112638941A
(zh)
|
2018-05-14 |
2021-04-09 |
免疫医疗有限公司 |
针对lif的抗体及其剂量形式
|
CA3100544A1
(en)
|
2018-05-17 |
2019-11-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
JP2021523878A
(ja)
|
2018-05-18 |
2021-09-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病aを処置する方法
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
CN112165974A
(zh)
|
2018-05-31 |
2021-01-01 |
诺华股份有限公司 |
乙型肝炎抗体
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
EP3805400A4
(de)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit veränderter halbwertszeit im cytoplasma
|
JP7457661B2
(ja)
|
2018-06-04 |
2024-03-28 |
バイオジェン・エムエイ・インコーポレイテッド |
低減したエフェクター機能を有する抗vla-4抗体
|
EP3802610A1
(de)
|
2018-06-05 |
2021-04-14 |
Amgen Inc. |
Modulation von körperabhängiger zellphagozytose
|
CN112243444A
(zh)
|
2018-06-08 |
2021-01-19 |
豪夫迈·罗氏有限公司 |
具有减少的翻译后修饰的肽接头
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CN112955178A
(zh)
|
2018-06-18 |
2021-06-11 |
免疫医疗有限公司 |
用于治疗癌症的、lif抑制剂和基于铂的抗肿瘤剂的组合
|
EP3810269A2
(de)
|
2018-06-19 |
2021-04-28 |
Atarga, LLC |
Antikörpermoleküle zur ergänzung der komponente 5 und deren verwendungen
|
JP2021527714A
(ja)
|
2018-06-20 |
2021-10-14 |
インサイト・コーポレイションIncyte Corporation |
抗pd−1抗体及びその使用
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
SG11202013163TA
(en)
|
2018-06-29 |
2021-01-28 |
Incyte Corp |
Formulations of an axl/mer inhibitor
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
BR112020026512A2
(pt)
|
2018-07-03 |
2021-04-06 |
Bristol-Myers Squibb Company |
Formulações de fgf-21
|
JP2021528988A
(ja)
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の二重特異性アゴニスト4−1bb抗原結合分子
|
SG11202100096XA
(en)
|
2018-07-09 |
2021-02-25 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
US20210155707A1
(en)
|
2018-07-10 |
2021-05-27 |
National University Corporation Kobe University |
ANTI-SIRPalpha ANTIBODY
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ácido
|
WO2020018715A1
(en)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
TW202017944A
(zh)
|
2018-07-20 |
2020-05-16 |
美商表面腫瘤學公司 |
抗cd112r組合物及方法
|
JP7368007B2
(ja)
|
2018-07-24 |
2023-10-24 |
グッド ティー セルズ、 インコーポレイテッド |
免疫関連疾患の予防または治療用組成物
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
WO2020027279A1
(en)
|
2018-08-01 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
AU2019312831A1
(en)
|
2018-08-01 |
2021-02-18 |
Centre National De La Recherche Scientifique - Cnrs - |
Anti-BTN3a antibodies and their use in treating cancer or infectious disorders
|
DE102018213030A1
(de)
|
2018-08-03 |
2020-02-06 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
|
EA202190435A1
(ru)
|
2018-08-03 |
2021-06-30 |
Эмджен Рисерч (Мюник) Гмбх |
Конструкции на основе антител для связывания cldn18.2 и cd3
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3608674A1
(de)
|
2018-08-09 |
2020-02-12 |
Regeneron Pharmaceuticals, Inc. |
Verfahren zur beurteilung der bindungsaffinität einer antikörpervariante an den neonatalen fc-rezeptor
|
KR20210042128A
(ko)
|
2018-08-09 |
2021-04-16 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
|
EP3833443A1
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigenbindende mittel, die cd277 binden, und verwendungen davon
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
SG11202003531WA
(en)
|
2018-08-10 |
2020-05-28 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗tigit抗体
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
WO2020047187A1
(en)
|
2018-08-29 |
2020-03-05 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting egfr
|
CN112771077A
(zh)
|
2018-08-31 |
2021-05-07 |
瑞泽恩制药公司 |
针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US20220008549A1
(en)
|
2018-09-06 |
2022-01-13 |
Daiichi Sankyo Company, Limited |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
US20210317479A1
(en)
|
2018-09-06 |
2021-10-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
KR20210057726A
(ko)
|
2018-09-07 |
2021-05-21 |
화이자 인코포레이티드 |
항-αvβ8 항체 및 그의 조성물 및 용도
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
CA3110530A1
(en)
|
2018-09-11 |
2020-03-19 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
KR20210061341A
(ko)
|
2018-09-13 |
2021-05-27 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
신규한 lilrb4 항체 및 이의 용도
|
WO2020061210A1
(en)
|
2018-09-18 |
2020-03-26 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
US20220177587A1
(en)
|
2018-09-19 |
2022-06-09 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP4249917A3
(de)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnosemethoden für dreifach-negativen brustkrebs
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
CA3113826A1
(en)
|
2018-09-27 |
2020-04-02 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
CN113286812A
(zh)
|
2018-09-27 |
2021-08-20 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
KR20210068408A
(ko)
|
2018-09-28 |
2021-06-09 |
암젠 인크 |
가용성 bcma에 대한 항체
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
SG11202102477QA
(en)
|
2018-10-01 |
2021-04-29 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
CN113286808A
(zh)
|
2018-10-23 |
2021-08-20 |
蜻蜓疗法股份有限公司 |
异二聚体Fc融合蛋白
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
SG11202103334YA
(en)
|
2018-10-26 |
2021-05-28 |
Hoffmann La Roche |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
KR20210087472A
(ko)
|
2018-11-01 |
2021-07-12 |
산동 뉴 타임 파마슈티칼 코., 리미티드. |
이중 특이성 항체 및 그 용도
|
EP3877407A1
(de)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von zwei kettenproteinen in prokaryotischen wirtszellen
|
EP3876957A1
(de)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Behandlung von für anti-pd-1-antikörper refraktären nsclc-patienten
|
CN112969477A
(zh)
|
2018-11-07 |
2021-06-15 |
第一三共株式会社 |
改善肽的血液动力学的方法
|
SG11202105010UA
(en)
|
2018-11-16 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
KR20210094610A
(ko)
|
2018-11-26 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
c-Kit에 대한 인간화 항체
|
US20210115130A1
(en)
|
2018-11-27 |
2021-04-22 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-il-23p19 antibody and use thereof
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
AU2019390394B2
(en)
|
2018-11-28 |
2023-11-30 |
Forty Seven, Inc. |
Genetically modified HSPCs resistant to ablation regime
|
JP2022510276A
(ja)
|
2018-11-30 |
2022-01-26 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Cd86バリアント免疫調節タンパク質およびその使用
|
MX2021006578A
(es)
|
2018-12-05 |
2021-07-07 |
Genentech Inc |
Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
CA3120059A1
(en)
|
2018-12-14 |
2020-06-18 |
Boehringer Ingelheim Io Canada Inc. |
Anti-periostin antibodies and uses thereof
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
EP3898667A2
(de)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modifizierter antikörper fcs und verwendungsverfahren
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
CN113194952A
(zh)
|
2018-12-20 |
2021-07-30 |
诺华股份有限公司 |
Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
|
EP3898671A1
(de)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
An vegf und il-1beta bindender antikörper und verfahren zur verwendung
|
KR20210107025A
(ko)
|
2018-12-21 |
2021-08-31 |
제넨테크, 인크. |
세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
|
SG11202106629PA
(en)
|
2018-12-21 |
2021-07-29 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
AU2019405782A1
(en)
|
2018-12-21 |
2021-06-17 |
23Andme, Inc. |
Anti-IL-36 antibodies and methods of use thereof
|
MX2021007769A
(es)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Proteínas de unión anti-ctla4 enmascaradas activables.
|
CN111378045B
(zh)
|
2018-12-28 |
2022-08-02 |
长春金赛药业有限责任公司 |
二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
|
US11447551B2
(en)
|
2018-12-28 |
2022-09-20 |
Sparx Bioscience Limited |
Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
|
JP2022515543A
(ja)
|
2018-12-30 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗ウサギcd19抗体および使用方法
|
JP2022516635A
(ja)
|
2019-01-04 |
2022-03-01 |
リゾルブ セラピューティクス, エルエルシー |
ヌクレアーゼ融合タンパク質によるシェーグレン病の処置
|
CR20210373A
(es)
|
2019-01-08 |
2021-08-19 |
H Lundbeck As |
Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
CN115120716A
(zh)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
CA3127072A1
(en)
|
2019-01-16 |
2020-07-23 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
KR20230128134A
(ko)
|
2019-01-22 |
2023-09-01 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
|
KR20210118881A
(ko)
|
2019-01-22 |
2021-10-01 |
제넨테크, 인크. |
면역글로불린 a 항체 및 생산과 이용의 방법
|
AU2020211976A1
(en)
|
2019-01-23 |
2021-07-15 |
Genentech, Inc. |
Methods of producing multimeric proteins in eukaryotic host cells
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
EP3914708A1
(de)
|
2019-01-24 |
2021-12-01 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
MX2021009138A
(es)
|
2019-02-05 |
2021-09-10 |
Seagen Inc |
Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
GB2599229A
(en)
|
2019-02-21 |
2022-03-30 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
CA3131953A1
(en)
|
2019-03-01 |
2020-09-10 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
CA3131305A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
EP3935083A4
(de)
|
2019-03-03 |
2022-11-30 |
Prothena Biosciences Limited |
Antikörper zur erkennung von tau
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
TW202100556A
(zh)
|
2019-03-14 |
2021-01-01 |
美商建南德克公司 |
使用her2 t細胞依賴性雙特異性抗體之治療
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
US20220152215A1
(en)
|
2019-03-15 |
2022-05-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting CEA
|
WO2020190731A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
US20220168440A1
(en)
|
2019-03-25 |
2022-06-02 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine deprivative conjugate
|
JP2022526334A
(ja)
|
2019-03-25 |
2022-05-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
新たなタウ種を標的化することによるタウオパチー障害の処置の方法
|
CA3139180A1
(en)
|
2019-03-27 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
CA3135430A1
(en)
|
2019-03-29 |
2020-10-08 |
Atarga, Llc |
Anti fgf23 antibody
|
JP2022521850A
(ja)
|
2019-04-03 |
2022-04-12 |
ジェンザイム・コーポレーション |
断片化が低減した抗アルファベータtcr結合ポリペプチド
|
CA3136488A1
(en)
|
2019-04-08 |
2020-10-15 |
Biogen Ma Inc. |
Anti-integrin antibodies and uses thereof
|
JP2022528721A
(ja)
|
2019-04-09 |
2022-06-15 |
アブクロ,インク. |
キラー細胞レクチン様受容体サブファミリーgメンバー1(klrg1)除去抗体
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
US11136353B2
(en)
|
2019-04-15 |
2021-10-05 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
|
AU2020257238A1
(en)
|
2019-04-17 |
2021-12-02 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
|
CA3133909A1
(en)
|
2019-04-18 |
2020-10-22 |
Elpida TSIKA |
Novel molecules for therapy and diagnosis
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
AU2020257748A1
(en)
|
2019-04-19 |
2021-11-18 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor recognizing modification site of antibody
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
CN114450022A
(zh)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
分离部分及其使用方法
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
AU2020279731A1
(en)
|
2019-05-20 |
2022-01-06 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
CN114728077A
(zh)
|
2019-05-20 |
2022-07-08 |
诺华股份有限公司 |
Mcl-1抑制剂抗体-药物缀合物及使用方法
|
AU2020279224A1
(en)
|
2019-05-21 |
2021-12-16 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
EP3972998A1
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19-bindende moleküle und verwendungen davon
|
AU2020278907A1
(en)
|
2019-05-23 |
2022-01-20 |
Ac Immune Sa |
Anti-TDP-43 binding molecules and uses thereof
|
US11591388B2
(en)
|
2019-06-07 |
2023-02-28 |
argenx BV |
Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
|
BR112021024938A2
(pt)
|
2019-06-12 |
2022-01-25 |
Novartis Ag |
Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
|
EP3983520A1
(de)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automatisierte biomassebasierte perfusionssteuerung zur herstellung von biologika
|
KR20220034784A
(ko)
|
2019-06-13 |
2022-03-18 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
|
TW202112822A
(zh)
|
2019-06-17 |
2021-04-01 |
美商威特拉公司 |
針對cd138之人類化抗體分子及其用途
|
US20220387608A1
(en)
|
2019-06-18 |
2022-12-08 |
Bayer Aktiengesellschaft |
Adrenomedullin-analogues for long-term stabilization and their use
|
WO2020255016A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
CA3141238A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis b virus (hbv) vaccines and uses thereof
|
WO2020255019A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
WO2020255022A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
|
WO2020255035A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
|
TW202114731A
(zh)
|
2019-06-18 |
2021-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合
|
US20220305116A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences lreland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
JP2022537324A
(ja)
|
2019-06-18 |
2022-08-25 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
B型肝炎ウイルス(hbv)ワクチンおよび抗pd-1抗体の組合せ
|
CA3140707A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
|
WO2020255013A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
|
WO2020255015A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
CA3141003A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
|
CN114630675A
(zh)
|
2019-06-18 |
2022-06-14 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
|
WO2020255017A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
WO2020254876A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Virus-like particle delivery of hepatitis b virus (hbv) vaccines
|
WO2020255008A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
WO2020255042A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
|
US20220305114A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
|
MX2021015537A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
|
WO2020254357A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
CA3140318A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
MX2021015648A
(es)
|
2019-06-19 |
2022-02-03 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
MX2021015540A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
EP3986563A1
(de)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipidnanopartikel oder liposomenabgabe von hepatitis-b-virus-(hbv)-impfstoffen
|
MA56534A
(fr)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
WO2020260327A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with sirt-1 gene knockout
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
CN113993888A
(zh)
|
2019-06-28 |
2022-01-28 |
豪夫迈·罗氏有限公司 |
产生抗体的方法
|
CN114401992A
(zh)
|
2019-07-05 |
2022-04-26 |
艾欧麦克斯治疗股份公司 |
结合igsf11(vsig3)的igc2的抗体及其用途
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
JP2022540904A
(ja)
|
2019-07-15 |
2022-09-20 |
ブリストル-マイヤーズ スクイブ カンパニー |
ヒトtrem-1に対する抗体およびその使用
|
JP2022540674A
(ja)
|
2019-07-15 |
2022-09-16 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗trem-1抗体およびその使用
|
EP3999540A1
(de)
|
2019-07-16 |
2022-05-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifizität für cd38 und verwendungen davon
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
US20220267453A1
(en)
|
2019-07-26 |
2022-08-25 |
Saitama Medical University |
Antibody recognizing extracellular region of alk2/acvr1
|
AU2020323893A1
(en)
|
2019-07-26 |
2022-02-17 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
WO2021021837A2
(en)
|
2019-07-29 |
2021-02-04 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
EP4004050A2
(de)
|
2019-07-30 |
2022-06-01 |
QLSF Biotherapeutics Inc. |
Multispezifische bindungsverbindung mit bindung an lfrrc15 und cd3
|
AU2020319677A1
(en)
|
2019-07-31 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
|
CN115068604A
(zh)
|
2019-07-31 |
2022-09-20 |
豪夫迈·罗氏有限公司 |
通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
KR102509648B1
(ko)
|
2019-08-06 |
2023-03-15 |
아프리노이아 테라퓨틱스 리미티드 |
병리학적 타우 종에 결합하는 항체 및 이의 용도
|
WO2021023860A1
(en)
|
2019-08-07 |
2021-02-11 |
Db Biotech, As |
Improved horseradish peroxidase polypeptides
|
JP2022545368A
(ja)
|
2019-08-12 |
2022-10-27 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
4-1bbおよび0x40結合タンパク質ならびに関連する組成物および方法、4-1bbに対する抗体、0x40に対する抗体
|
GB201912437D0
(en)
|
2019-08-30 |
2019-10-16 |
Glaxosmithkline Ip Dev Ltd |
CR2 Binding Proteins and their use in Medical Therapy
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
US20220347312A1
(en)
|
2019-09-04 |
2022-11-03 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate Synthesis Method
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
WO2021048135A1
(en)
|
2019-09-09 |
2021-03-18 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
EP4028416A1
(de)
|
2019-09-10 |
2022-07-20 |
Amgen Inc. |
Reinigungsverfahren für bispezifische antigen-bindende polypeptide mit erhöhter dynamischer bindungskapazität beim protein-l-einfang
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
MX2022003110A
(es)
|
2019-09-18 |
2022-06-27 |
Lamkap Bio Alpha AG |
Anticuerpos biespecificos contra ceacam5 y cd3.
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
JP2022548292A
(ja)
|
2019-09-19 |
2022-11-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
酸性pHでVISTAと結合する抗体
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
MX2022003610A
(es)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
CA3152600A1
(en)
|
2019-09-30 |
2021-04-08 |
Andrew KROETSCH |
Lentiviral vector formulations
|
MX2022003740A
(es)
|
2019-09-30 |
2022-05-02 |
Bolt Biotherapeutics Inc |
Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
|
WO2021067776A2
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
CN114650843A
(zh)
|
2019-10-04 |
2022-06-21 |
Tae生命科学有限责任公司 |
包括fc突变和位点特异性缀合性质的抗体组合物
|
JP2022553129A
(ja)
|
2019-10-08 |
2022-12-22 |
ネクチン セラピューティクス エルティーディー. |
ポリオウイルス受容体(pvr)に対する抗体およびその使用
|
CN114829404A
(zh)
|
2019-10-09 |
2022-07-29 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
CA3158298A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
MX2022004769A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Inhibidores de tim-3 y sus usos.
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
EP4048309A4
(de)
|
2019-10-24 |
2024-02-21 |
Prometheus Biosciences Inc |
Humanisierte antikörper gegen tnf-like ligand 1a (tl1a) und deren verwendungen
|
AU2020369652A1
(en)
|
2019-10-25 |
2022-05-12 |
Bolt Biotherapeutics, Inc. |
Thienoazepine immunoconjugates, and uses thereof
|
WO2021086953A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Compositions and methods for prophylaxis of hiv
|
US20230002785A1
(en)
|
2019-10-28 |
2023-01-05 |
Georgia Tech Research Corporation |
Mrna-encoded antibodies for contraception
|
MX2022005132A
(es)
|
2019-11-04 |
2022-08-15 |
Compugen Ltd |
Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
EP4058485A1
(de)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
|
EP3822288A1
(de)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Gegen das cd276-antigen gerichtete antikörper, und andere modulatoren gegen das cd276-antigen, und deren verwendung
|
WO2021110995A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
EP4069736A1
(de)
|
2019-12-04 |
2022-10-12 |
MedImmune Limited |
Antikörper gegen lif und verwendungen davon
|
EP4069742A1
(de)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypische antikörper gegen gprc5d-gerichtete bindungsdomänen und verwandte zusammensetzungen und verfahren
|
KR20220122653A
(ko)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Bcma-표적 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
WO2021127528A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
EP4077389A1
(de)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Kombination des anti-tim-3-antikörpers mbg453 und des anti-tgf-beta-antikörpers nis793 mit oder ohne decitabin oder dem anti-pd-1-antikörper spartalizumab zur behandlung von myelofibrose und des myelodysplastischen syndroms
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
PE20221585A1
(es)
|
2019-12-27 |
2022-10-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
EP4085251A1
(de)
|
2020-01-02 |
2022-11-09 |
F. Hoffmann-La Roche AG |
Verfahren zum bestimmen der menge eines therapeutischen antikörpers im gehirn
|
US20210205311A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
TW202136314A
(zh)
|
2020-01-06 |
2021-10-01 |
美商法西尼克斯股份有限公司 |
抗ccr8抗體及其用途
|
BR112022013554A2
(pt)
|
2020-01-08 |
2022-09-06 |
argenx BV |
Métodos para tratar distúrbios do pênfigo
|
CN115243763A
(zh)
|
2020-01-08 |
2022-10-25 |
里珍纳龙药品有限公司 |
治疗进行性骨化性纤维发育不良
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
WO2021146383A1
(en)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
EP4093772A1
(de)
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1-antikörper
|
CN115151308A
(zh)
|
2020-01-21 |
2022-10-04 |
博尔特生物治疗药物有限公司 |
抗pd-l1抗体
|
EP4093771A1
(de)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
|
US11597770B2
(en)
|
2020-01-24 |
2023-03-07 |
Pfizer Inc. |
Anti-E-selectin antibodies, compositions and methods of use
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
IL295387A
(en)
|
2020-02-05 |
2022-10-01 |
Larimar Therapeutics Inc |
Peptide-binding proteins and their uses
|
EP4100426A1
(de)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 und verwendungen davon
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
KR20220145871A
(ko)
|
2020-02-25 |
2022-10-31 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
암 치료 방법
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
CA3169910A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
US11879004B2
(en)
|
2020-02-28 |
2024-01-23 |
Genzyme Corporation |
Modified binding polypeptides for optimized drug conjugation
|
AU2021225920A1
(en)
|
2020-02-28 |
2022-09-15 |
Shanghai Henlius Biotech, Inc. |
Anti-CD137 construct and use thereof
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
AU2021230226A1
(en)
|
2020-03-06 |
2022-09-29 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|
JP2023516724A
(ja)
|
2020-03-06 |
2023-04-20 |
オーエヌエー セラピューティクス エセ.エレ. |
抗cd36抗体及び癌を治療するためのそれらの使用
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
CN115605507A
(zh)
|
2020-03-13 |
2023-01-13 |
基因泰克公司(Us) |
抗白介素-33抗体及其用途
|
CN115003333A
(zh)
|
2020-03-13 |
2022-09-02 |
江苏恒瑞医药股份有限公司 |
Pvrig结合蛋白及其医药用途
|
CN117510630A
(zh)
|
2020-03-19 |
2024-02-06 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
EP4121459A1
(de)
|
2020-03-19 |
2023-01-25 |
Amgen Inc. |
Antikörper gegen mucin 17 und verwendungen davon
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
MX2022011800A
(es)
|
2020-03-26 |
2023-01-19 |
Seagen Inc |
Metodos para tratar mieloma multiple.
|
EP4127153A2
(de)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modifizierte säugetierzellen mit reduzierten wirtszellproteinen
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
CN115397850A
(zh)
|
2020-03-30 |
2022-11-25 |
豪夫迈·罗氏有限公司 |
与vegf和pdgf-b结合的抗体及其使用方法
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
CA3170570A1
(en)
|
2020-04-01 |
2021-10-07 |
James J. KOBIE |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021203024A1
(en)
|
2020-04-03 |
2021-10-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
KR20210124867A
(ko)
|
2020-04-06 |
2021-10-15 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
|
EP4132971A1
(de)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinitätsgereifte anti-lap-antikörper und verwendungen davon
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
CN116249712A
(zh)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
Tau结合化合物
|
JP2023522972A
(ja)
|
2020-04-22 |
2023-06-01 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
TW202206459A
(zh)
|
2020-04-24 |
2022-02-16 |
瑞士商赫孚孟拉羅股份公司 |
硫氫基化合物及其衍生物的酶以及途徑調節
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
WO2021222935A2
(en)
|
2020-04-28 |
2021-11-04 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
EP4143345A1
(de)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
IL297806A
(en)
|
2020-04-30 |
2022-12-01 |
Sairopa B V |
Anti-cd103 antibodies
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
CN115461363A
(zh)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
免疫球蛋白变体
|
MX2022013616A
(es)
|
2020-05-01 |
2022-11-16 |
Bolt Biotherapeutics Inc |
Anticuerpos anti-dectina-2.
|
EP4146283A1
(de)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antikörper-wirkstoff-konjugate (adcs) mit einem anti-trop-2-antikörper, zusammensetzungen mit solchen adcs sowie verfahren zur herstellung und verwendung davon
|
MX2022013999A
(es)
|
2020-05-08 |
2023-02-16 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas.
|
EP4146282A1
(de)
|
2020-05-08 |
2023-03-15 |
Bolt Biotherapeutics, Inc. |
Elastase-substrat, peptidlinker-immunkonjugate und verwendungen davon
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
JP2023528235A
(ja)
|
2020-05-17 |
2023-07-04 |
アストラゼネカ・ユーケイ・リミテッド |
SARS-CoV-2抗体、並びにこれを選択及び使用する方法
|
WO2021236658A1
(en)
|
2020-05-19 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
US20230220057A1
(en)
|
2020-05-27 |
2023-07-13 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
MX2022014736A
(es)
|
2020-05-29 |
2023-03-23 |
23Andme Inc |
Anticuerpos anti-cd200r1 y metodos de uso de estos.
|
EP4157874A2
(de)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Die nebenwirkungen mindernde verabreichung eines bispezifischen antikörperkonstrukts, das an cd33 und cd3 bindet
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
AU2021283345A1
(en)
|
2020-06-02 |
2023-02-02 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
IL298111A
(en)
|
2020-06-02 |
2023-01-01 |
Arcus Biosciences Inc |
Antibodies to tigit
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
AU2021288916A1
(en)
|
2020-06-08 |
2022-11-24 |
F.Hoffmann-La Roche Ag |
Anti-HBV antibodies and methods of use
|
US20220119513A1
(en)
|
2020-06-08 |
2022-04-21 |
Zoetis Services Llc |
Anti-tgfb antibodies and therapeutic uses thereof
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
EP4169948A1
(de)
|
2020-06-22 |
2023-04-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-cd73-antikörper und verwendung davon
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
TW202216756A
(zh)
|
2020-06-24 |
2022-05-01 |
美商建南德克公司 |
具細胞凋亡抗性之細胞株
|
JP2023531722A
(ja)
|
2020-06-24 |
2023-07-25 |
ビステラ, インコーポレイテッド |
Aprilに対する抗体分子およびその使用
|
MX2022016322A
(es)
|
2020-06-25 |
2023-01-24 |
Merck Sharp & Dohme Llc |
Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
|
EP4171614A1
(de)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Behandlung des sjögren-syndroms mit nukleasefusionsproteinen
|
WO2022008027A1
(en)
|
2020-07-06 |
2022-01-13 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
KR20230037578A
(ko)
|
2020-07-10 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체
|
TW202216780A
(zh)
|
2020-07-17 |
2022-05-01 |
美商建南德克公司 |
抗notch2抗體及其使用方法
|
UY39337A
(es)
|
2020-07-23 |
2022-02-25 |
Othair Prothena Ltd |
Anticuerpos anti-abeta
|
BR112023001209A2
(pt)
|
2020-07-24 |
2023-02-14 |
Hoffmann La Roche |
Método para produzir um polipeptídeo de fusão-anticorpo-multímero
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
CN116507638A
(zh)
|
2020-07-31 |
2023-07-28 |
葛兰素史密斯克莱知识产权发展有限公司 |
抗原结合蛋白
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
MX2023001143A
(es)
|
2020-08-04 |
2023-02-22 |
Seagen Inc |
Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos.
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
KR20230044312A
(ko)
|
2020-08-06 |
2023-04-03 |
바이오버라티브 유에스에이 인코포레이티드 |
보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로
|
KR20230045613A
(ko)
|
2020-08-10 |
2023-04-04 |
아스트라제네카 유케이 리미티드 |
Covid-19의 치료 및 예방을 위한 sars-cov-2 항체
|
MX2023001679A
(es)
|
2020-08-13 |
2023-02-22 |
Bolt Biotherapeutics Inc |
Inmunoconjugados de pirazolazepina y usos de estos.
|
AR123254A1
(es)
|
2020-08-14 |
2022-11-16 |
Ac Immune Sa |
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
|
CR20230101A
(es)
|
2020-08-25 |
2023-04-28 |
Gilead Sciences Inc |
Moléculas de unión a antígeno multi- específicas contra el vih y métodos de uso
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
AU2021333779A1
(en)
|
2020-08-26 |
2023-04-13 |
Marengo Therapeutics, Inc. |
Methods of detecting TRBC1 or TRBC2
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4208201A1
(de)
|
2020-09-04 |
2023-07-12 |
F. Hoffmann-La Roche AG |
An vegf-a und ang2 bindender antikörper und verfahren zur verwendung
|
MX2023002901A
(es)
|
2020-09-14 |
2023-06-01 |
Ichnos Sciences SA |
Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
|
US20220154207A1
(en)
|
2020-09-24 |
2022-05-19 |
Hoffmann-La Roche Inc. |
Mammalian cell lines with gene knockout
|
EP4217394A1
(de)
|
2020-09-24 |
2023-08-02 |
Merck Sharp & Dohme LLC |
Stabile formulierungen von programmiert-tod-rezeptor-1-antikörpern und hyaluronidase-varianten und fragmenten davon sowie verfahren zur verwendung davon
|
EP4222172A1
(de)
|
2020-09-30 |
2023-08-09 |
Compugen Ltd. |
Kombinationstherapie mit anti-pvrig-antikörperformulierungen, anti-tigit-antikörpern und anti-pd-1-antikörpern
|
JP2023544407A
(ja)
|
2020-10-05 |
2023-10-23 |
ジェネンテック, インコーポレイテッド |
抗FcRH5/抗CD3二重特異性抗体による処置のための投与
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4225330A1
(de)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
|
WO2022076712A2
(en)
|
2020-10-07 |
2022-04-14 |
Zoetis Services Llc |
Anti-ngf antibodies and methods of use thereof
|
CA3187272A1
(en)
|
2020-10-08 |
2022-04-14 |
Thorsten Ross |
Trispecific binders
|
CA3198072A1
(en)
|
2020-10-09 |
2022-04-14 |
Pfizer Inc. |
Cd1a antibodies and uses thereof
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
WO2022082005A1
(en)
|
2020-10-16 |
2022-04-21 |
Qlsf Biotherapeutics, Inc. |
Multispecific binding compounds that bind to pd-l1
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
CN116829586A
(zh)
|
2020-10-21 |
2023-09-29 |
勃林格殷格翰国际有限公司 |
用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
WO2022090801A2
(en)
|
2020-10-26 |
2022-05-05 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
KR20230098317A
(ko)
|
2020-11-03 |
2023-07-03 |
도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 |
표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
EP4240758A1
(de)
|
2020-11-04 |
2023-09-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper
|
EP4240493A2
(de)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern und anti-cd79b-antikörper-wirkstoffkonjugaten
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
AU2021375733A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
JP2023547506A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
B細胞悪性腫瘍を治療するための抗cd19剤及びb細胞標的化剤の組み合わせ療法
|
MX2023005197A
(es)
|
2020-11-06 |
2023-05-16 |
Amgen Inc |
Dominio de union a antigeno con tasa de recorte reducida.
|
WO2022096700A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2023548538A
(ja)
|
2020-11-08 |
2023-11-17 |
シージェン インコーポレイテッド |
併用療法
|
EP4245321A1
(de)
|
2020-11-11 |
2023-09-20 |
Daiichi Sankyo Company, Limited |
Kombination aus einem antikörper-wirkstoff-konjugat und einem anti-sirpalpha-antikörper
|
CA3202759A1
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
CN116615252A
(zh)
|
2020-11-24 |
2023-08-18 |
诺华股份有限公司 |
抗cd48抗体、抗体药物缀合物及其用途
|
AU2021387970A1
(en)
|
2020-11-27 |
2023-06-29 |
General Nanotherapeutics Llc |
Methods and composition for treatment of immune-mediated diseases
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
JP2023551935A
(ja)
|
2020-12-02 |
2023-12-13 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Il-7結合タンパク質および医学的療法におけるそれらの使用
|
EP4255496A1
(de)
|
2020-12-02 |
2023-10-11 |
Westfälische Wilhelms-Universität Münster |
Elektrostatische nanopartikel und verwendung davon
|
US20220177535A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
CA3201818A1
(en)
|
2020-12-11 |
2022-06-16 |
Maria Fardis |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
JP2023552791A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗her2免疫複合体、及びその使用
|
WO2022125891A2
(en)
|
2020-12-11 |
2022-06-16 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
CN116744978A
(zh)
|
2020-12-11 |
2023-09-12 |
博尔特生物治疗药物有限公司 |
抗her2免疫缀合物及其用途
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
CN116723866A
(zh)
|
2020-12-11 |
2023-09-08 |
博尔特生物治疗药物有限公司 |
抗pd-l1免疫缀合物和其用途
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
EP4262827A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebs mit tumorinfiltrierenden lymphozyten
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
AU2021399841A1
(en)
|
2020-12-17 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
JP2023554456A
(ja)
|
2020-12-18 |
2023-12-27 |
チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド |
呼吸器合胞体ウイルスに特異的に結合する分子
|
EP4267734A1
(de)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonukleotide zum targeting von xbp1
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022135467A1
(zh)
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗b7-h3抗体及其用途
|
CA3207066A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
JP2024501845A
(ja)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
|
JP2024503826A
(ja)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1-lag3二重特異性抗体及びcd20 t細胞二重特異性抗体を用いる併用療法
|
EP4277705A1
(de)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
An krebszellen bindende geteilte antikörper und target-radionuklide an diese zellen
|
AU2022207624A1
(en)
|
2021-01-13 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
TW202245825A
(zh)
|
2021-01-20 |
2022-12-01 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4284422A1
(de)
|
2021-01-28 |
2023-12-06 |
Vaccinvent GmbH |
Verfahren und mittel zur modulation von b-zell-vermittelten immunantworten
|
WO2022165275A2
(en)
|
2021-01-28 |
2022-08-04 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
EP4284516A1
(de)
|
2021-01-28 |
2023-12-06 |
Compugen Ltd. |
Anti-pvrig-antikörperformulierungen und verwendungen davon
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
AR124712A1
(es)
|
2021-01-29 |
2023-04-26 |
Merck Sharp & Dohme |
Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
EP4288458A1
(de)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Degraderplattform für multispezifische bindungsproteine und verfahren zur verwendung
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
PE20231680A1
(es)
|
2021-02-17 |
2023-10-19 |
Dr Falk Pharma Gmbh |
Anticuerpos anti-cd30l y usos de estos
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗vista構築物およびその使用
|
EP4301138A2
(de)
|
2021-03-05 |
2024-01-10 |
Iovance Biotherapeutics, Inc. |
Tumorspeicherungs- und zellkulturzusammensetzungen
|
EP4304724A1
(de)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Kombinationstherapie aus pd-1-gerichtetem il-2-varianten-immunkonjugat und bispezifischen anti-tyrp1/anti-cd3-antikörpern
|
WO2022189377A1
(en)
|
2021-03-09 |
2022-09-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
AU2022232951A1
(en)
|
2021-03-10 |
2023-10-19 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
CA3212439A1
(en)
|
2021-03-19 |
2022-09-22 |
Michelle SIMPSON-ABELSON |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
WO2022204071A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
JP2024511414A
(ja)
|
2021-03-23 |
2024-03-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球のcish遺伝子編集及び免疫療法におけるその使用
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
WO2022204564A2
(en)
|
2021-03-25 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
TW202304520A
(zh)
|
2021-03-26 |
2023-02-01 |
美商博特生物治療公司 |
2-胺基-4-羧醯胺-苯并氮呯免疫結合物及其用途
|
BR112023019512A2
(pt)
|
2021-03-26 |
2023-10-31 |
Abcuro Inc |
Anticorpos anti-klrg1
|
KR20230163450A
(ko)
|
2021-03-26 |
2023-11-30 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
2-아미노-4-카복사마이드-벤즈아제핀 면역접합체 및 이의 용도
|
WO2022204529A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
TW202304508A
(zh)
|
2021-03-31 |
2023-02-01 |
美商百歐維拉提夫美國公司 |
減少冷凝集素疾病患者之手術相關溶血
|
WO2022212836A1
(en)
|
2021-04-01 |
2022-10-06 |
Pyxis Oncology, Inc. |
Gpnmb antibodies and methods of use
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4320147A2
(de)
|
2021-04-08 |
2024-02-14 |
Marengo Therapeutics, Inc. |
An tcr bindende multifunktionelle moleküle und verwendungen davon
|
JP2024514816A
(ja)
|
2021-04-09 |
2024-04-03 |
シージェン インコーポレイテッド |
抗tigit抗体を用いるがんの治療方法
|
WO2022218957A1
(en)
|
2021-04-12 |
2022-10-20 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
BR112023021475A2
(pt)
|
2021-04-16 |
2023-12-19 |
Novartis Ag |
Conjugados anticorpo-fármaco e métodos para produzir os mesmos
|
TW202305122A
(zh)
|
2021-04-19 |
2023-02-01 |
美商建南德克公司 |
經修飾之哺乳動物細胞
|
BR112023021665A2
(pt)
|
2021-04-19 |
2023-12-19 |
Iovance Biotherapeutics Inc |
Método para tratar um câncer, e, composição
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
KR20240019124A
(ko)
|
2021-05-07 |
2024-02-14 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
US20220389097A1
(en)
|
2021-05-14 |
2022-12-08 |
Genentech Inc. |
Agonists of TREM2
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
CA3219217A1
(en)
|
2021-05-21 |
2022-11-24 |
Andreas Faust |
Antibody-protamine fusions as targeting compounds of a protamine-based nanoparticle
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
EP4347656A1
(de)
|
2021-05-28 |
2024-04-10 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapien zur behandlung von krebs
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
CN117529330A
(zh)
|
2021-06-18 |
2024-02-06 |
纳米医疗有限公司 |
用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法
|
CA3219360A1
(en)
|
2021-06-22 |
2022-12-29 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
WO2023275621A1
(en)
|
2021-07-01 |
2023-01-05 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
CN115558023A
(zh)
|
2021-07-02 |
2023-01-03 |
安源医药科技(上海)有限公司 |
抗cd3抗体及其用途
|
CA3223534A1
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
WO2023288182A1
(en)
|
2021-07-12 |
2023-01-19 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CA3227742A1
(en)
|
2021-07-26 |
2023-02-02 |
Abcuro, Inc. |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Double structure antibodies
|
WO2023007472A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2022324406A1
(en)
|
2021-08-02 |
2024-03-14 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-cd79b×cd3 bispecific antibody and use thereof
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
WO2023019092A1
(en)
|
2021-08-07 |
2023-02-16 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
WO2023026245A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
IL310382A
(en)
|
2021-08-27 |
2024-03-01 |
Genentech Inc |
Methods for treating tau pathologies
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
EP4148067A1
(de)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Verfahren zur expression einer antikörper-multimer-fusion
|
TW202328439A
(zh)
|
2021-09-09 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
使用pd-1 talen基因減弱生成til產物之方法
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
TW202327650A
(zh)
|
2021-09-23 |
2023-07-16 |
美商思進公司 |
治療多發性骨髓瘤之方法
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
US20230192834A1
(en)
|
2021-09-27 |
2023-06-22 |
Zoetis Services Llc |
Anti- tgfb1,2,3 antibodies and therapeutic uses thereof
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
CA3232806A1
(en)
|
2021-09-30 |
2023-04-06 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
WO2023076599A1
(en)
|
2021-10-29 |
2023-05-04 |
Bolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023078968A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023081818A1
(en)
|
2021-11-05 |
2023-05-11 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
US20240041981A1
(en)
|
2021-12-01 |
2024-02-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
WO2023108137A1
(en)
|
2021-12-10 |
2023-06-15 |
Biogen Ma Inc. |
Modified actriib proteins and methods of use thereof
|
WO2023114829A1
(en)
|
2021-12-15 |
2023-06-22 |
Genentech, Inc. |
Stabilized il-18 polypeptides and uses thereof
|
WO2023114951A1
(en)
|
2021-12-17 |
2023-06-22 |
Viiv Healthcare Company |
Combination therapies for hiv infections and uses thereof
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023139107A1
(en)
|
2022-01-18 |
2023-07-27 |
argenx BV |
Galectin-10 antibodies
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023161457A1
(en)
|
2022-02-27 |
2023-08-31 |
Evobright Gmbh |
Bispecific antibodies against cd277 and a tumor-antigen
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
WO2023192802A1
(en)
|
2022-04-01 |
2023-10-05 |
The Board Of Trustees Of The University Of Illinois |
Notch1 and notch4 decoys and methods of use
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201268A1
(en)
|
2022-04-13 |
2023-10-19 |
Gilead Sciences, Inc. |
Combination therapy for treating tumor antigen expressing cancers
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
TW202400637A
(zh)
|
2022-04-25 |
2024-01-01 |
美商威特拉公司 |
April之抗體分子及其用途
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
US20230348604A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
TW202400638A
(zh)
|
2022-05-10 |
2024-01-01 |
法商感應檢查療法公司 |
用於治療胃腸發炎病症之方法的抗btn3a抗體
|
WO2023217933A1
(en)
|
2022-05-11 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf-a and il6 and methods of use
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023218099A1
(en)
|
2022-05-13 |
2023-11-16 |
argenx BV |
In utero treatment of a fetus having genetic disease/neuromuscular disease
|
WO2023227641A1
(en)
|
2022-05-27 |
2023-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023237928A2
(en)
|
2022-06-10 |
2023-12-14 |
Horizon Therapeutics Ireland Dac |
Igf1r antibodies
|
US20240117021A1
(en)
|
2022-06-15 |
2024-04-11 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023242362A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn/antigen-binding molecules and methods of use
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024026496A1
(en)
|
2022-07-28 |
2024-02-01 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024030982A2
(en)
|
2022-08-02 |
2024-02-08 |
Diadem Spa |
Device for detection and prognostic assessment of neurodegenerative disorders
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024044675A1
(en)
|
2022-08-25 |
2024-02-29 |
Beigene, Ltd. |
Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064752A2
(en)
|
2022-09-20 |
2024-03-28 |
Yale University |
Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
WO2024061930A1
(en)
|
2022-09-22 |
2024-03-28 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
|
WO2024068777A1
(en)
|
2022-09-28 |
2024-04-04 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Modified ace2 proteins with improved activity against sars-cov-2
|